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Abstract 3 
Abstract 
 
Cognitive deficits in abstinent MDMA users were reported in various domains. The findings regarding 
attention, working memory, and executive function deficits are inconclusive, and were criticized for 
being induced by the co-use of other drugs. 
Moreover, social cognition and social decision-making have rarely been investigated in chronic 
MDMA users but in animals, long-lasting depletions of oxytocin (OXT) have been reported after 
chronic MDMA treatment implicating a potential impact on social cognition and behavior. 
The present thesis aims to eliminate the issue of unreliable self-reported drug use by investigating 
social and non-social cognition and social decision-making in objectively verified pure and polydrug 
MDMA users. Additionally, plasma OXT levels of a subsample were investigated. 
Verified pure MDMA users showed large deficits in declarative memory, while MDMA users with a 
co-use of stimulants shoved additional and stronger impairments in working memory and executive 
functions. Main MDMA users showed higher cognitive empathy but did not differ from controls in 
emotional empathy. Moreover, MDMA users acted less self-serving. However, higher hair MDMA 
values went along with a decrease in cognitive empathy. OXT plasma levels did not significantly 
differ between the two groups.  
Overall, our results suggest that even pure chronic MDMA users display strong impairments in 
declarative memory and that the broad cognitive impairments in polydrug MDMA users are driven by 
stimulant co-use. Additionally, they suggest that people with high cognitive empathy might be more 
prone to use MDMA chronically, which likely leads to a decrease in cognitive empathy.  
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Zusammenfassung 
 
Bei chronischen MDMA Konsumenten wurden eine Vielzahl an kognitiven Defiziten berichtet. Die 
Befundlage bezüglich Arbeitsgedächtnis, Aufmerksamkeit und exekutiven Funktionen scheint 
unschlüssig, wobei vor allem die Erfassung des Drogenkonsums mittels Befragung häufig kritisiert 
wurde. 
Die soziale Kognition und das soziale Entscheidungsverhalten wurden zudem in chronischen MDMA 
Konsumenten erst spärlich untersucht. In Tierversuchen konnte nach wiederholter MDMA Gabe eine 
langfristige Senkung des Oxytocinspiegels beobachtet werden, was einen Einfluss auf das 
Sozialverhalten nahelegt.  
Durch die objektive Messung des Drogenkonsums mittels Haaranalysen wird im Rahmen dieser 
Arbeit das Problem des selbstberichteten Drogenkonsums zu beseitigen versucht. Dazu wird die 
soziale und nicht-soziale Kognition, das soziale Entscheidungsverhalten sowie 
Blutplasmaoxytocinspiegel von reinen und polytoxischen MDMA Konsumenten erhoben. Es zeigten 
sich bereits bei reinen MDMA Konsumenten erhebliche Einschränkungen des deklarativen 
Gedächtnisses. Zusätzlich zeigten MDMA Konsumenten eine höhere kognitive Empathie, wobei sie 
sich in der emotionalen Empathie nicht von den Kontrollen unterschieden. Dazu verhielten sie sich 
prosozialer als die Kontrollgruppe. Höhere MDMA Haarwerte gingen mit einer Abnahme der 
kognitiven Empathie einher. Oxytocinspiegel unterschieden sich nicht signifikant zwischen den 
Gruppen. 
Zusammen genommen zeigen diese Resultate, dass bereits reine MDMA Konsumenten starke 
Einbussen im deklarativen Gedächtnis zeigen und dass breitgefächerte und starke kognitive 
Beeinträchtigungen bei polytoxischen MDMA Konsumenten wahrscheinlich durch den Co-Konsum 
von Stimulanzien induziert sind. Personen mit hoher kognitiver Empathie und prosozialem Verhalten 
neigen möglicherweise zu MDMA Konsum. Dieser könnte aber chronisch ausgeprägt zu Einbussen in 
der kognitiven Empathie führen.  
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1 General Introduction  
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1.1 Outline 
The substance 3,4-methylenedioxymethamphetamine (MDMA), better known under its street name 
Ecstasy (Gouzoulis-Mayfrank and Daumann, 2006), was first researched on laboratory animals in 
1953 (Hardman et al., 1973), but it was not until 1978 when the first publication of its 
psychopharmacological effects in humans was published (Shulgin and Nichols, 1978), 66 years after 
its first synthesis in 1912 (Shulgin, 1986; Benzenhofer and Passie, 2010). In the mid-1980s, the 
recreational use of MDMA commenced, which entailed empirical studies investigating physiological, 
psychobiological as well as psychiatric effects of the drug (Shulgin, 1986; Peroutka et al., 1988; 
Peroutka, 1989; McCann and Ricaurte, 1991; Parrott et al., 2017). Hereby, McCann and Ricaurte 
(1991) reported retrospective memory deficits in two abstinent MDMA users for the first time. In 
subsequent years, evidence for memory deficits, which were often measured via delayed recall tasks, 
accumulated (Laws and Kokkalis, 2007; Parrott et al., 2017). Up to now, cognitive deficits in abstinent 
MDMA users were reported in various other cognitive domains also, including attention, working 
memory, and executive functions (Kalechstein et al., 2007). However, the findings regarding deficits 
in these four domains are inconclusive on the one hand, and were criticized for possibly being 
confounded by the co-consumption of drugs other than MDMA itself on the other hand (Cole, 2014). 
Therefore, the aim of our first study was to partial out the cognitive deficits possibly caused by long-
term MDMA consumption and to delimit them from those deficits possibly induced by a polydrug use 
pattern.  
Social cognition is an important predictor for the development and course of drug addiction because 
deficits in social cognition are associated with social isolation, depression, and aggression, which 
support the maintenance of drug use (Homer et al., 2008; Volkow et al., 2011). Despite the importance 
of social cognition for the topic of drug use in general, social cognition and social decision making, 
was mainly investigated  in the context of acute effects of MDMA (Hysek et al., 2012; Hysek et al., 
2014b; Hysek et al., 2014a; Schmid et al., 2014; Kuypers et al., 2017), while long-term effects were 
less often researched (Reay et al., 2006). This is no surprise, given that the main subjective effects and 
the main reason for consumption are increased prosocial feelings (Morgan et al., 2013). These 
prosocial effects of MDMA have been proposed to be mediated by an increased oxytocin release 
(Thompson et al., 2007). Given that chronic administration of MDMA leads to a long-lasting depletion 
of oxytocin in animal models (van Nieuwenhuijzen et al., 2010), it was predicted that MDMA has a 
detrimental effect on the oxytocin system and consequently on social cognition in human users, which 
is what we wanted to investigate in our second study.  
In sum, the present thesis has two main goals. (1) To partial out the main cognitive long-term effects 
of chronic MDMA consumption from the effects of polydrug co-use on the one hand (Study 1), and to 
describe the long-term effects of chronic MDMA consumption on social cognitive performance and 
social decision making on the other hand (Study 2). 
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1.2 General facts about MDMA 
MDMA was first synthesized by the chemical company Merck in Germany in 1912 and later patented 
in 1914 (Siegel, 1986). Its primary effects are blocking and reversing the serotonin (5-HT) transporter, 
therefore acting as an indirect antagonist on the 5-HT system. Via transporter-mediated exchange, 5-
HT is released through the 5-HT transporter, which leads to a significant increase in synaptically 
available 5-HT, especially because MDMA also increases the amount of available 5-HT by inducing 
5-HT efflux from vesicles (Rudnick and Wall, 1992; Kalant, 2001). MDMA also acts on dopaminergic 
and noradrenergic neurotransmitter systems, but the main psychological effects of MDMA were 
shown to depend on 5-HT release, whereas stimulant-like euphoric effects are a consequence of 
dopamine receptor stimulation (Liechti and Vollenweider, 2001). Typically, MDMA is consumed 
orally while a recreational dose contains 70 to 120mg of MDMA (Parrott, 2004). MDMA leads to 
psychological effects including euphoria and well-being together with increased sociability, feelings of 
closeness with others, elevated self-confidence, and reduced inhibition (Vollenweider et al., 1998; 
Bedi et al., 2010). These acute effects of MDMA – which last for about three to five hours (Kolbrich 
et al., 2008) – were described as entactogenic and empathogenic, which is why MDMA has been 
labeled a entactogens and empathogen in contrast to stimulants or hallucinogens that differ from 
MDMA in their psychoactive profile (Nichols, 1986; Bedi et al., 2009). After oral consumption, 
MDMA is detectable in the blood after 30 minutes, while the highest plasma concentrations occur 
after one to three hours after consumption. The elimination half-life of typical recreational doses of 
MDMA is about eight to nine hours (Mas et al., 1999). 
 
 
1.3 Epidemiology of MDMA use 
The United Nations Office on Drugs and Crime (2016) estimated that worldwide, 19.4 million people 
consumed MDMA in 2014. This number increased in 2015 to 21.65 million past year users (United 
Nations Office on Drugs and Crime, 2017) and shows, that MDMA is one of the most used illicit 
drugs worldwide.  
Also in Europe, MDMA was the third most consumed illegal drug (after cannabis and cocaine) with 
14 million last year users between 15 and 64 years of age, which equals 4.2% of the people in this age 
range (European Monitoring Centre for Drugs and Drug Addiction, 2017). For the age range of 15 to 
34 years, 2.3 million young adults consumed MDMA in the past year, which equals 1.8% of this age 
group. 
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In Switzerland, the Federal Office of Public Health (Gmel et al., 2016) estimated that people aged over 
15 have a last-year prevalence of 0.3%, while the last-year prevalence is highest for adults aged 20 to 
24 years with 1.5%.  
Finally, applying wastewater analyses – an innovative approach to measure drug use on a community 
level – Been et al. (2016) revealed that in Zurich, the measured load of MDMA per 1000 inhabitants is 
highest and lowest in the city of Lugano.  
 
1.4 MDMA use and cognition 
Broadly speaking, brain regions associated with drug addiction extend over those responsible for 
cognitive functions (Gould, 2010). In the following chapter, the connection between MDMA-induced 
neurological alterations and cognitive functions, especially declarative memory function, will be 
outlined.  
As described above, the consumption of MDMA leads to an acute immense neuronal release of 5-HT 
but also of noradrenalin (Rothman et al., 2001; Cadet et al., 2007). Consequently, the neurotoxic 
effects of MDMA primarily involve the 5-HT system and in rats and even in non-human primates, 
detrimental effects of large doses of MDMA on 5-HT neurons were reported already in the 1980s 
(Schmidt et al., 1986; Ricaurte et al., 1988). In general, evidence for the neurodegeneration hypothesis 
of MDMA from animal studies can be summarized as follows. After single or multiple administrations 
of large doses of MDMA, forebrain levels of 5-HT and 5-hydoxyindoleacetic acid (main 5-HT 
metabolite) decrease, and synaptosomal 5-HT uptake, and radiolabeled 5-HT transporter (SERT) 
binding is reduced 1 to 2 weeks after the last drug administration (Biezonski and Meyer, 2011), while 
dopaminergic and noradrenergic neurotransmitter systems remain undamaged (Insel et al., 1989; 
Biezonski and Meyer, 2011).  
In humans, as mentioned before, the first cognitive impairments in the context of MDMA use were 
reported by McCann and Ricaurte (1991) and encompassed self-reported retrospective memory 
deficits (Parrott et al., 2017). Consequently, declarative memory deficits were the first deficits to be 
associated with MDMA use (Krystal et al., 1992). In subsequent years, evidence for a relationship 
between MDMA consumption and memory deficits were delivered in two ways (Kuypers et al., 2016). 
(1) Placebo-controlled studies have shown that 75mg of MDMA acutely leads to a significant lower 
recall performance on recall tests (immediate as well as delayed recall) 1.5 hours after intake (Kuypers 
and Ramaekers, 2005; Kuypers et al., 2013; de Sousa Fernandes Perna et al., 2014). Studies in which 
MDMA was given to participants also revealed that after 25.5 hours (after MDMA administration), the 
subject’s memory performance was equal to the placebo control group’s showing that a single dose of 
MDMA does not lead to permanent verbal memory deficits (Kuypers and Ramaekers, 2005). (2) The 
second source of evidence for memory deficits in the context of MDMA consumption are 
retrospective studies, which investigated if these acute effects can become chronic after the substance 
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was used regularly. In a huge systematical review, Rogers et al. (2009) conclude that immediate and 
delayed verbal memory deficits are associated with MDMA use. Similarly, Kalechstein et al. (2007) 
found strong effects for the neurocognitive domain of verbal learning and memory in their meta-
analytic review, while non-verbal learning, attention, and executive function only reached small to 
moderate effect sizes.  
Evidence for a linkage between MDMA consumption and cognitive impairments not only comes from 
observational investigations (Quednow et al., 2006), but also from a linkage on the 
neurological/neuroanatomical level. MDMA induced decreases in SERT levels were found in a variety 
of brain regions, including the dorsolateral prefrontal cortex (DLPFC) (Roberts et al., 2016), which is 
responsible for encoding, recall, and recognition of memory content (Ranganath et al., 2003). 
Reviews and the reviewed retrospective studies themselves were repeatedly criticized because of 
methodological concerns (Curran, 2000; Cole, 2014). The main criticism are polydrug co-use, possible 
impurity of ecstasy tablets, and that drug use patterns are usually self-reported by the study 
participants (Kuypers et al., 2016). The fact that MDMA consumption is often measured via self-
reports (drug interviews) together with the fact that MDMA users tend to co-use other drugs (Schifano 
et al., 1998) raises concern about the validity of past findings, because consequently, cross-sectional 
studies cannot conclusively attribute performance differences between MDMA users and drug-naïve 
controls to MDMA use alone (Curran, 2000). Additionally drug users might be motivated to give a 
biased self-report or they might over- or underestimate their drug use because of memory alterations 
(Magura and Kang, 1996; Quednow et al., 2006).  
To bypass this problem, we objectively quantified our participants’ drug use via toxicological hair 
testing. This allowed us to distinguish between relatively pure MDMA users, whose hair analyses did 
not reveal co-consumption of stimulants, and so called polydrug MDMA users, which mainly 
consumed stimulants additionally.  
In sum, the literature has repeatedly shown declarative memory impairments in chronic MDMA users 
(Parrott, 2001; Kalechstein et al., 2007), while attention, working memory, and executive functions 
were reported to be impaired less consistently and with lower effect sizes. Because we suspected that 
the reason for inconsistencies regarding deficits in attention, working memory, and executive 
functions might lie in the methodological issues presented above, we aimed to control polydrug co-use 
by hair analyses in our first study.  
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1.5 MDMA use and social cognition 
Social cognition refers to different mental operations which underlie everyday social interactions 
(Fiske and Taylor, 1991). This concept includes the recognition of emotions, mental perspective taking 
also referred to as Theory of Mind (ToM), and empathy (Davis, 1983; Blair, 2005; Dziobek et al., 
2008), while the two concepts of ToM and empathy partially overlap. This is because empathy is 
conceptualized as having two components, the cognitive and the emotional empathy. Cognitive 
empathy encompasses the ability to decode and understand emotions and mental states (ToM) of 
others (Baron-Cohen and Wheelwright, 2004; Blair, 2005), and emotional empathy describes a 
person’s emotional response to another’s emotional state (Blair, 2005; Dziobek et al., 2008). The acute 
effects of MDMA on social cognition are of interest, because MDMA users reported to use the 
substance with the intention of initiating empathic feelings and enhance sociability (Morgan et al., 
2013; Schmid et al., 2014). A number of studies have investigated subjective experiences of MDMA 
(Bedi et al., 2010) and found, among others, increases in perceived empathy and self-related 
friendliness, extroversion, sociability, amicability, gregariousness and closeness to others 
(Vollenweider et al., 1999; Tancer and Johanson, 2007; Kolbrich et al., 2008; Dumont et al., 2009). 
In animals, the acute effects of MDMA on social behavior, which is often measured with the social 
interaction test, have been researched extensively. Hereby, rodents are exposed to unfamiliar 
conspecifics and behaviors like adjacent lying and friendly following are measured (Kamilar-Britt and 
Bedi, 2015). Both measures were consistently reported to be increased in rats after the administration 
of 5mg/kg to 15mg/kg and 2.5mg/kg to 10mg/kg of MDMA respectively (Ando et al., 2006; 
Thompson et al., 2009; Kamilar-Britt and Bedi, 2015). Together with decreased aggression and 
elevated social reward, literature consistently suggests a prosocial effect profile of MDMA in rodents 
(Kamilar-Britt and Bedi, 2015). In humans, acute effects on social cognition have been researched 
recently, while the literature mostly focusses on effects on cognitive and emotional empathy (Hysek et 
al., 2012; Hysek et al., 2014b; Schmid et al., 2014). 
Regarding cognitive empathy, acute MDMA intake has repeatedly been shown to reduce the 
identification of negative emotional stimuli such as fear or anger in others (Bedi et al., 2010; Hysek et 
al., 2012; Hysek et al., 2014b; Hysek et al., 2014a; Kirkpatrick et al., 2014) and one study additionally 
found an increased recognition of friendliness in others, a positive emotional stimuli (Hysek et al., 
2012). Thus, MDMA may – based on the increased recognition of positive emotional stimuli and the 
decreased recognition of negative emotional stimuli but also because of the induced prosocial states – 
facilitate social behavior (Kirkpatrick et al., 2014) and social decision making.  
In summary, research on empathy performance suggests that acute MDMA intake decreases cognitive 
empathy but enhances emotional empathy (Kamilar-Britt and Bedi, 2015). Interestingly, these acute 
prosocial effects of MDMA have been linked to the release of central oxytocin (OXT), which is a 
peptide that plays a crucial role in social bonding in mammalians (Bos et al., 2012). Several studies 
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have found dose-dependent increases in blood plasma OXT levels after MDMA administration (Wolff 
et al., 2006; Dumont et al., 2009; Hysek et al., 2012; Schmid et al., 2014) which correlated with 
increased feelings of sociability (Dumont et al., 2009). Given that a former animal study documented 
lasting depletion of brain OXT after long-term MDMA administration (van Nieuwenhuijzen et al., 
2010), we investigated social cognition and social decision making together with blood plasma OXT 
levels in abstinent, long-term MDMA users. For the same reasons as already mentioned in the chapter 
before – 1) MDMA users often co-use other drugs (Schifano et al., 1998; Curran, 2000), 2) research 
has been criticized for unreliably measuring past drug use through drug interviews (Cole, 2014), and 
3) drug users might be motivated to give a biased self-report or simply over- or underestimate their 
own consumption because of consistently shown memory alterations (Magura and Kang, 1996; 
Quednow et al., 2006) – we objectively determined drug use through quantitative hair analyses.  
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1.6 Research objectives 
Altogether, evidence accumulated for an association between the repeated use of MDMA and deficits 
in the cognitive functions of attention, working memory, executive functions and declarative memory. 
However, it is unclear what part of these impairments may be due to polydrug and especially stimulant 
co-consumption. For social cognition and social decision-making, the performance of long-term 
MDMA users has not been described to date. Therefore, this thesis is designed to help clarify the role 
of chronic, long-term MDMA use and polydrug co-use with regard to cognitive functioning and to 
further assess social cognition, social decision making and blood plasma OXT levels in main chronic 
users of MDMA.  
In order to examine these issues, we conducted two studies (chapter 2 and 3). In the first study 
(chapter 2), we investigated a cross-sectional sample of 26 pure MDMA users, 25 polydrug MDMA 
users and 56 MDMA- and drug-naïve healthy controls with a comprehensive neuropsychological test 
battery. In the second study (chapter 3), we analyzed an overlapping study sample consisting of all the 
pure MDMA users from the first study (26) and 12 polydrug MDMA users, for which MDMA was the 
first drug of choice.  
As described before, the lack of control for polydrug consumption is a major issue in MDMA 
research. Accordingly, data from these studies that objectively measure drug use via toxicological hair 
analyses will enable us to entangle cognitive impairments possibly induced by chronic MDMA 
consumption from those induced by polydrug co-use in study 1. In study 2, the objective hair drug 
values will enable us to precisely characterize social cognition and social decision making of long-
term MDMA users in contrast to MDMA- and drug-naïve controls. 
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1.7 Data collection  
This thesis was part of the Zurich Cocaine Cognition Study (ZuCo2St) which started in 2010. The 
project was supervised by Prof. Dr. rer. nat. Boris Quednow, head of the Division of Experimental and 
Clinical Pharmacopsychology at the University Hospital of Psychiatry in Zurich and funded by the 
Swiss National Science Foundation (SNSF, grants PP00P1-123516/1 and PP00P1-146326/1). The 
ZuCo2St was designed to assess the long-term consequences of cocaine use on different measures of 
social and non-social cognition, impulsivity, and decision-making with the possibility to extend the 
recruitment to participants consuming other drugs than cocaine. To recruit the participants for this 
thesis, a new recruitment phase was started in August 2014, which lasted until August 2015. The data 
were collected in Zurich and participants were recruited via online media and flyer advertisements as 
well as via word of mouth. In total, 53 long-term MDMA users and 56 drug and MDMA-naïve 
controls were recruited. All subjects were aged between 18 and 60 years and had sufficient German 
language skills. As a special feature of the studies constituting this thesis, the group allocation was not 
only based on the participants self-reported drug consumption, but on objective hair analyses. These 
hair analyses enabled us to quantify the participant’s use of 17 substances and metabolites for up to the 
last 6 months prior to testing. In the first study – where our focus was on the cogntive difference 
between pure and polydrug MDMA users – we compared 26 pure MDMA users with 25 polydrug 
MDMA users (and 56 controls) after two participants were excluded because of missing/deficient hair 
samples. In the second study – where we focused on main MDMA users that consume MDMA as their 
main drug of choice – we excluded an addition 13 MDMA users because their hair analyses implied a 
preference for stimulants over MDMA in the past half year. We therefore compared 38 main MDMA 
users with 56 drug and MDMA-naïve controls in the second study investigating social cognition and 
interaction.  
Introduction 17 
1.8 References 
Ando RD, Benko A, Ferrington L, Kirilly E, Kelly PA, Bagdy G (2006) Partial lesion of the 
serotonergic system by a single dose of MDMA results in behavioural disinhibition and enhances 
acute MDMA-induced social behaviour on the social interaction test. Neuropharmacology 
50:884-896. 
Baron-Cohen S, Wheelwright S (2004) The empathy quotient: an investigation of adults with Asperger 
syndrome or high functioning autism, and normal sex differences. J Autism Dev Disord 34:163-
175. 
Bedi G, Hyman D, de Wit H (2010) Is ecstasy an "empathogen"? Effects of +/-3,4-
methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in 
others. Biol Psychiatry 68:1134-1140. 
Bedi G, Phan KL, Angstadt M, de Wit H (2009) Effects of MDMA on sociability and neural response 
to social threat and social reward. Psychopharmacology (Berl) 207:73-83. 
Been F, Bijlsma L, Benaglia L, Berset JD, Botero-Coy AM, Castiglioni S, Kraus L, Zobel F, Schaub 
MP, Bucheli A, Hernandez F, Delemont O, Esseiva P, Ort C (2016) Assessing geographical 
differences in illicit drug consumption--A comparison of results from epidemiological and 
wastewater data in Germany and Switzerland. Drug Alcohol Depend 161:189-199. 
Benzenhofer U, Passie T (2010) Rediscovering MDMA (ecstasy): the role of the American chemist 
Alexander T. Shulgin. Addiction 105:1355-1361. 
Biezonski DK, Meyer JS (2011) The Nature of 3, 4-Methylenedioxymethamphetamine (MDMA)-
Induced Serotonergic Dysfunction: Evidence for and Against the Neurodegeneration Hypothesis. 
Current Neuropharmacology 9:84-90. 
Blair RJ (2005) Responding to the emotions of others: dissociating forms of empathy through the 
study of typical and psychiatric populations. Conscious Cogn 14:698-718. 
Bos PA, Panksepp J, Bluthe RM, van Honk J (2012) Acute effects of steroid hormones and 
neuropeptides on human social-emotional behavior: a review of single administration studies. 
Front Neuroendocrinol 33:17-35. 
Cadet JL, Krasnova IN, Jayanthi S, Lyles J (2007) Neurotoxicity of substituted amphetamines: 
molecular and cellular mechanisms. Neurotox Res 11:183-202. 
Cole JC (2014) MDMA and the "ecstasy paradigm". J Psychoactive Drugs 46:44-56. 
Curran HV (2000) Is MDMA ('Ecstasy') neurotoxic in humans? An overview of evidence and of 
methodological problems in research. Neuropsychobiology 42:34-41. 
Davis MH (1983) Measuring individual differences in empathy: Evidence for a multidimensional 
approach. J Pers Soc Psychol 44:113-126. 
de Sousa Fernandes Perna EB, Theunissen EL, Kuypers KP, Heckman P, de la Torre R, Farre M, 
Ramaekers JG (2014) Memory and mood during MDMA intoxication, with and without 
memantine pretreatment. Neuropharmacology 87:198-205. 
Dumont GJ, Sweep FC, van der Steen R, Hermsen R, Donders AR, Touw DJ, van Gerven JM, 
Buitelaar JK, Verkes RJ (2009) Increased oxytocin concentrations and prosocial feelings in 
humans after ecstasy (3,4-methylenedioxymethamphetamine) administration. Soc Neurosci 
4:359-366. 
Dziobek I, Rogers K, Fleck S, Bahnemann M, Heekeren HR, Wolf OT, Convit A (2008) Dissociation 
of cognitive and emotional empathy in adults with Asperger syndrome using the Multifaceted 
Empathy Test (MET). J Autism Dev Disord 38:464-473. 
European Monitoring Centre for Drugs and Drug Addiction (2017) European Drug Report 2017: 
Trends and Delvelopments. In, p 104. Luxembourg: Publications Office of the European Union. 
Fiske ST, Taylor SE (1991) Social cognition, 2nd Edition. New York: McGraw-Hill. 
Gmel G, Kuendig H, Notari L, Gmel C (2016) Suchtmonitoring Schweiz - Konsum von Alkohol, 
Tabak und illegalen Drogen in der Schweiz im Jahr 2015. Sucht Schweiz, Lausanne, Schweiz. 
Gould TJ (2010) Addiction and cognition. Addict Sci Clin Pract 5:4-14. 
Gouzoulis-Mayfrank E, Daumann J (2006) Neurotoxicity of methylenedioxyamphetamines (MDMA; 
ecstasy) in humans: how strong is the evidence for persistent brain damage? Addiction 101:348-
361. 
Introduction 18 
Hardman HF, Haavik CO, Seevers MH (1973) Relationship of the structure of mescaline and seven 
analogs to toxicity and behavior in five species of laboratory animals. Toxicol Appl Pharmacol 
25:299-309. 
Homer BD, Solomon TM, Moeller RW, Mascia A, DeRaleau L, Halkitis PN (2008) 
Methamphetamine abuse and impairment of social functioning: a review of the underlying 
neurophysiological causes and behavioral implications. Psychol Bull 134:301-310. 
Hysek CM, Domes G, Liechti ME (2012) MDMA enhances "mind reading" of positive emotions and 
impairs "mind reading" of negative emotions. Psychopharmacology (Berl) 222:293-302. 
Hysek CM, Simmler LD, Schillinger N, Meyer N, Schmid Y, Donzelli M, Grouzmann E, Liechti ME 
(2014a) Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA 
administered alone or in combination. Int J Neuropsychopharmacol 17:371-381. 
Hysek CM, Schmid Y, Simmler LD, Domes G, Heinrichs M, Eisenegger C, Preller KH, Quednow BB, 
Liechti ME (2014b) MDMA enhances emotional empathy and prosocial behavior. Soc Cogn 
Affect Neurosci 9:1645-1652. 
Insel TR, Battaglia G, Johannessen JN, Marra S, De Souza EB (1989) 3,4-
Methylenedioxymethamphetamine ("ecstasy") selectively destroys brain serotonin terminals in 
rhesus monkeys. J Pharmacol Exp Ther 249:713-720. 
Kalant H (2001) The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. CMAJ 
165:917-928. 
Kalechstein AD, De La Garza R, 2nd, Mahoney JJ, 3rd, Fantegrossi WE, Newton TF (2007) MDMA 
use and neurocognition: a meta-analytic review. Psychopharmacology (Berl) 189:531-537. 
Kamilar-Britt P, Bedi G (2015) The prosocial effects of 3,4-methylenedioxymethamphetamine 
(MDMA): Controlled studies in humans and laboratory animals. Neurosci Biobehav Rev 57:433-
446. 
Kirkpatrick MG, Lee R, Wardle MC, Jacob S, de Wit H (2014) Effects of MDMA and Intranasal 
oxytocin on social and emotional processing. Neuropsychopharmacology 39:1654-1663. 
Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA (2008) Physiological and 
subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J 
Clin Psychopharmacol 28:432-440. 
Krystal JH, Price LH, Opsahl C, Ricaurte GA, Heninger GR (1992) Chronic 3,4-
methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological 
function? Am J Drug Alcohol Abuse 18:331-341. 
Kuypers KP, Ramaekers JG (2005) Transient memory impairment after acute dose of 75mg 3.4-
Methylene-dioxymethamphetamine. J Psychopharmacol 19:633-639. 
Kuypers KP, Dolder PC, Ramaekers JG, Liechti ME (2017) Multifaceted empathy of healthy 
volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies. J 
Psychopharmacol:269881117699617. 
Kuypers KP, de la Torre R, Farre M, Pujadas M, Ramaekers JG (2013) Inhibition of MDMA-induced 
increase in cortisol does not prevent acute impairment of verbal memory. Br J Pharmacol 
168:607-617. 
Kuypers KP, Theunissen EL, van Wel JH, de Sousa Fernandes Perna EB, Linssen A, Sambeth A, 
Schultz BG, Ramaekers JG (2016) Verbal Memory Impairment in Polydrug Ecstasy Users: A 
Clinical Perspective. PLoS One 11:e0149438. 
Laws KR, Kokkalis J (2007) Ecstasy (MDMA) and memory function: a meta-analytic update. Hum 
Psychopharmacol 22:381-388. 
Liechti ME, Vollenweider FX (2001) Which neuroreceptors mediate the subjective effects of MDMA 
in humans? A summary of mechanistic studies. Hum Psychopharmacol 16:589-598. 
Magura S, Kang SY (1996) Validity of self-reported drug use in high risk populations: a meta-
analytical review. Subst Use Misuse 31:1131-1153. 
Mas M, Farre M, de la Torre R, Roset PN, Ortuno J, Segura J, Cami J (1999) Cardiovascular and 
neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in 
humans. J Pharmacol Exp Ther 290:136-145. 
McCann UD, Ricaurte GA (1991) Lasting neuropsychiatric sequelae of (+-
)methylenedioxymethamphetamine ('ecstasy') in recreational users. J Clin Psychopharmacol 
11:302-305. 
Introduction 19 
Morgan CJ, Noronha LA, Muetzelfeldt M, Feilding A, Curran HV (2013) Harms and benefits 
associated with psychoactive drugs: findings of an international survey of active drug users. J 
Psychopharmacol 27:497-506. 
Nichols DE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic 
hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 
18:305-313. 
Parrott AC (2001) Human psychopharmacology of Ecstasy (MDMA): a review of 15 years of 
empirical research. Hum Psychopharmacol 16:557-577. 
Parrott AC (2004) Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing 
MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology (Berl) 
173:234-241. 
Parrott AC, Downey LA, Roberts CA, Montgomery C, Bruno R, Fox HC (2017) Recreational 3,4-
methylenedioxymethamphetamine or 'ecstasy': Current perspective and future research prospects. 
J Psychopharmacol:269881117711922. 
Peroutka SJ (1989) 'Ecstasy': a human neurotoxin? Arch Gen Psychiatry 46:191. 
Peroutka SJ, Newman H, Harris H (1988) Subjective effects of 3,4-methylenedioxymethamphetamine 
in recreational users. Neuropsychopharmacology 1:273-277. 
Quednow BB, Jessen F, Kuhn KU, Maier W, Daum I, Wagner M (2006) Memory deficits in abstinent 
MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction. J Psychopharmacol 
20:373-384. 
Ranganath C, Johnson MK, D'Esposito M (2003) Prefrontal activity associated with working memory 
and episodic long-term memory. Neuropsychologia 41:378-389. 
Reay JL, Hamilton C, Kennedy DO, Scholey AB (2006) MDMA polydrug users show process-
specific central executive impairments coupled with impaired social and emotional judgement 
processes. J Psychopharmacol 20:385-388. 
Ricaurte GA, Forno LS, Wilson MA, DeLanney LE, Irwin I, Molliver ME, Langston JW (1988) (+/-
)3,4-Methylenedioxymethamphetamine selectively damages central serotonergic neurons in 
nonhuman primates. JAMA 260:51-55. 
Roberts CA, Jones A, Montgomery C (2016) Meta-analysis of molecular imaging of serotonin 
transporters in ecstasy/polydrug users. Neurosci Biobehav Rev 63:158-167. 
Rogers G, Elston J, Garside R, Roome C, Taylor R, Younger P, Zawada A, Somerville M (2009) The 
harmful health effects of recreational ecstasy: a systematic review of observational evidence. 
Health Technol Assess 13:iii-iv, ix-xii, 1-315. 
Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS (2001) 
Amphetamine-type central nervous system stimulants release norepinephrine more potently than 
they release dopamine and serotonin. Synapse 39:32-41. 
Rudnick G, Wall SC (1992) The molecular mechanism of "ecstasy" [3,4-methylenedioxy-
methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin 
release. Proc Natl Acad Sci U S A 89:1817-1821. 
Schifano F, Di Furia L, Forza G, Minicuci N, Bricolo R (1998) MDMA ('ecstasy') consumption in the 
context of polydrug abuse: a report on 150 patients. Drug Alcohol Depend 52:85-90. 
Schmid Y, Hysek CM, Simmler LD, Crockett MJ, Quednow BB, Liechti ME (2014) Differential 
effects of MDMA and methylphenidate on social cognition. J Psychopharmacol 28:847-856. 
Schmidt CJ, Wu L, Lovenberg W (1986) Methylenedioxymethamphetamine: a potentially neurotoxic 
amphetamine analogue. Eur J Pharmacol 124:175-178. 
Shulgin AT (1986) The background and chemistry of MDMA. J Psychoactive Drugs 18:291-304. 
Shulgin AT, Nichols DE (1978) Characterization of three new psychotomimetics. The Pharmacology 
of Hallucinogens New York: Pergamon. 
Siegel RK (1986) MDMA. Nonmedical use and intoxication. J Psychoactive Drugs 18:349-354. 
Tancer M, Johanson CE (2007) The effects of fluoxetine on the subjective and physiological effects of 
3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 
189:565-573. 
Thompson MR, Hunt GE, McGregor IS (2009) Neural correlates of MDMA ("Ecstasy")-induced 
social interaction in rats. Soc Neurosci 4:60-72. 
Introduction 20 
Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS (2007) A role for oxytocin and 5-
HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine ("ecstasy"). 
Neuroscience 146:509-514. 
United Nations Office on Drugs and Crime (2016) World Drug Report 2016. In. Vienna: United 
Nations Publication. 
United Nations Office on Drugs and Crime (2017) World Drug Report 2017. In. Vienna: United 
Nations Publication. 
van Nieuwenhuijzen PS, Long LE, Hunt GE, Arnold JC, McGregor IS (2010) Residual social, 
memory and oxytocin-related changes in rats following repeated exposure to gamma-
hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination. 
Psychopharmacology (Berl) 212:663-674. 
Volkow ND, Baler RD, Goldstein RZ (2011) Addiction: pulling at the neural threads of social 
behaviors. Neuron 69:599-602. 
Vollenweider FX, Gamma A, Liechti M, Huber T (1998) Psychological and cardiovascular effects and 
short-term sequelae of MDMA ("ecstasy") in MDMA-naive healthy volunteers. 
Neuropsychopharmacology 19:241-251. 
Vollenweider FX, Remensberger S, Hell D, Geyer MA (1999) Opposite effects of 3,4-
methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy 
humans. Psychopharmacology (Berl) 143:365-372. 
Wolff K, Tsapakis EM, Winstock AR, Hartley D, Holt D, Forsling ML, Aitchison KJ (2006) 
Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing 
population. J Psychopharmacol 20:400-410. 
  
2 Discrete memory impairments in 
largely pure chronic users of 
MDMA  
 
 
 
Michael D. Wunderli1, Matthias Vonmoos1, Marina Fürst1, Katrin Schädelin1, Thomas Kraemer2, Markus R. 
Baumgartner2, Erich Seifritz3,4, Boris B. Quednow1*  
 
 
1  Experimental and Clinical Pharmacopsychology, Department of Psychiatry, Psychotherapy, and Psychosomatics, 
University Hospital of Psychiatry, University of Zurich, Switzerland  
2  Center of Forensic Hairanalytics, Institute of Forensic Medicine, University of Zurich, Switzerland  
3  Department of Psychiatry, Psychotherapy, and Psychosomatics, University Hospital of Psychiatry, University of Zurich, 
Switzerland  
4  Neuroscience Center Zurich, University of Zurich and Swiss Federal Institu8te of Technology Zurich, Switzerland 
* Corresponding author 
 
 
Personal Contribution 
BBQ designed this study and all authors contributed to its planning, analysis strategy and interpretation of the data. BBQ, 
MV, MF, KS, and MDW were responsible for the neuropsychological assessment of the study participants. Qualitative urine 
and hair testing was performed by MRB and TK. Statistical analyses were conducted by MDW under the supervision of 
BBQ. All authors had access to the data and the statistical outputs and critically revised the article after MDW had drafted it. 
All authors approved the final manuscript. 
 
Study 1 – MDMA and cognition 22 
2.1 Abstract 
Background: Chronic use of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) has 
repeatedly been associated with deficits in working memory, declarative memory, and executive 
functions. However, previous findings regarding working memory and executive function are 
inconclusive yet, as in most studies concomitant stimulant use, which is known to affect these 
functions, was not adequately controlled for.  
 
Methods: Therefore, we compared the cognitive performance of 26 stimulant-free and largely pure 
(primary) MDMA users, 25 stimulant-using polydrug MDMA users, and 56 MDMA/stimulant-naïve 
controls by applying a comprehensive neuropsychological test battery. Neuropsychological tests were 
grouped into four cognitive domains. Recent drug use was objectively quantified by 6-month hair 
analyses on 17 substances and metabolites.  
 
Results: Considerably lower mean hair concentrations of stimulants (amphetamine, 
methamphetamine, methylphenidate, cocaine), opioids (morphine, methadone, codeine), and 
hallucinogens (ketamine, 2C-B) were detected in primary compared to polydrug users, while both user 
groups did not differ in their MDMA hair concentration. Cohen’s d effect sizes for both comparisons, 
i.e., primary MDMA users vs. controls and polydrug MDMA users vs. controls, were highest for 
declarative memory (dprimary=.90, dpolydrug=1.21), followed by working memory (dprimary=.52, 
dpolydrug=.96), executive functions (dprimary=.46, dpolydrug=.86), and attention (dprimary=.23, dpolydrug=.70).  
 
Conclusion: Primary MDMA users showed strong and relatively discrete declarative memory 
impairments, whereas MDMA polydrug users displayed broad and unspecific cognitive impairments. 
Consequently, even largely pure chronic MDMA use is associated with decreased performance in 
declarative memory, while additional deficits in working memory and executive functions displayed 
by polydrug MDMA users are likely driven by stimulant co-use. 
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2.2 Introduction 
With a global estimate of 19.4 million users in 2014 (United Nations Office on Drugs and Crime, 
2016) 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) remains one of the most used illicit 
drugs worldwide. MDMA is a synthetic substituted amphetamine derivate that blocks and reverses the 
monoamine transporters leading to a rapid release of monoamines, especially of serotonin (5-HT) but 
also of noradrenalin and dopamine (Rudnick and Wall, 1992; Kalant, 2001). In rodents and in non-
human primates, research found evidence for long-term loss of 5-HT nerve terminals (Commins et al., 
1987; Ricaurte et al., 1988; Hatzidimitriou et al., 1999). In humans, MDMA-related reductions of 5-
HT transporters in different regions of the basal ganglia and the neocortex have been reported 
analogously (for review see Roberts et al., 2016a). Over the past three decades, the behavioral effects 
of MDMA use have been investigated extensively, and a broad range of cognitive dysfunctions has 
been reported in long-term MDMA users (Parrott, 2013). 
While declarative memory impairments have been consistently shown in MDMA users with moderate 
to large effect sizes (for review see Kalechstein et al., 2007; Parrott, 2013), other cognitive domains 
yielded inconclusive results. The meta-analysis from Laws and Kokkalis (2007) found a medium 
effect size (d=0.63) for working memory (short-term memory) deficits in recreational MDMA users, 
but also reported that impairments are likely driven by verbal working memory deficits, whereas 
visual working memory may be primarily affected by cannabis use. On the other hand, working 
memory deficits found in the often applied (immediate) prose recall task (Morgan, 1999), which 
measures verbal working (immediate recall) and declarative memory (delayed recall), could not be 
replicated by all investigators (e.g., Thomasius et al., 2003; 2006). Moreover, a meta-regression over 
12 comparisons revealed that differences in immediate prose recall between MDMA users (or ex-
MDMA users) and controls are partially ascribable to the group’s unequal intelligence status (Rogers 
et al., 2009). For delayed recall tasks (declarative memory), the same bias was found, but, in contrast 
to working memory performance, differences between MDMA users and controls remained significant 
after controlling for intelligence status (Rogers et al., 2009).  
Regarding potential attention deficits in MDMA users, results seem to differ between studies 
investigating basic or higher order attention: Some studies examining basic attention or vigilance 
reported no impairments (Rodgers, 2000; e.g., Back-Madruga et al., 2003; Parrott, 2013), in contrast to 
studies investigating higher order sustained attention that found strong impairments (McCann et al., 
1999; Fox et al., 2001). However, in a meta-analytic review, Kalechstein (2007) reported only small to 
moderate effect sizes for attention/concentration deficits in MDMA users compared to matched 
controls. For executive functions, a recent meta-analysis by Roberts et al. (2016b) investigated four 
components of executive functions: inhibition, switching, updating (Miyake et al., 2000), and access 
(Fisk and Sharp, 2004) and found that – compared to non-MDMA polydrug using controls – polydrug 
MDMA users display significant alterations with a small effect size in all functions with exception of 
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the unaffected inhibition component. However, the authors state that they cannot rule out the 
possibility that concomitant drug use contributed to the deficits found in executive functioning of the 
polydrug MDMA users. 
Inconsistencies and interpretation difficulties within findings for cognitive deficits in long-term 
MDMA users – especially regarding working memory and attention - are apparent and may be 
partially explained by different factors limiting the interpretation of results. Perhaps the most serious 
disadvantages of human MDMA research are that drug consumption is mostly measured via self-
reports (drug interviews) and that MDMA users often use other drugs (Schifano et al., 1998). 
Consequently, the interpretation of performance differences between MDMA users and controls in 
cross-sectional studies cannot be attributed solely to MDMA use (Curran, 2000). This is evident in 
experiments comparing polydrug MDMA users with drug-naïve controls, as possible long-term effects 
cannot be distinguished from the effects of other drugs. Also, in experiments with a non-MDMA 
polydrug control group, possible interaction effects between MDMA and other drugs may mask the 
pure effects of MDMA. Lastly, studies investigating non-polydrug MDMA users that do not 
quantitatively objectify (e.g., by toxicological hair testing) drug use remain unaware of the truth-value 
of the reported drug use patterns assessed with drug interviews. Because drug users might have 
different motivations to give a biased self-report or simply over- or underestimate their own 
consumption because of consistently shown memory alterations, we objectively quantified drug use 
through hair analyses in the present study. 
To our knowledge, no study has investigated cognitive alterations in a sample of objectively 
confirmed pure MDMA users so far. Thus, we compared largely pure (in the following also called 
“primary” MDMA users) and polydrug MDMA users with drug-naïve healthy controls on well-
established cognitive tasks. Drug use during the last months was objectively determined by 
quantitative hair analyses for all participants. We hypothesized that largely pure MDMA users still 
show disturbed declarative memory functions with a strong effect size, whereas other cognitive 
domains are only slightly or moderately impaired. In contrast, we expect stimulant-using polydrug 
MDMA users to show additional impairments in working memory, executive functions and attention 
given that these cognitive domains have been shown to be affected by cocaine (Jovanovski et al., 
2005; Vonmoos et al., 2013; Vonmoos et al., 2014), amphetamine (Lundqvist, 2005), and 
methamphetamine use (Scott et al., 2007).  
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2.3 Method 
2.3.1 Participants 
Within the context of the Zurich Cocaine Cognition Study (ZuCo2St), which has started in 2010 
(Vonmoos et al., 2013; Quednow, 2016), we recruited 53 long-term MDMA users and 56 drug-naïve, 
healthy controls by means of flyer and online media advertisements. Prior to testing, candidates 
underwent a brief telephone screening to assess their study eligibility. All subjects had to be aged 
between 18 and 60 years and had to have sufficient German language skills. Based on the results of 
the hair analyses (see below), 25 MDMA users were classified as polydrug MDMA users, 26 were 
classified as primary MDMA users and 2 MDMA users were excluded because of deficient/missing 
hair samples. Participants were categorized as primary MDMA users only if their hair analyses 
revealed MDMA consumption and the hair cocaine and amphetamine concentrations – the most 
common co-used drugs in our sample – did not exceed the cut-off values of 500pg/mg or 200pg/mg 
respectively (Cooper et al., 2012). Based on these cut-off values, we consequently classified 
participants as polydrug MDMA users if their amphetamine or cocaine hair concentrations exceeded 
these values and MDMA metabolites were detected (see Table 1 and Supplementary Table S1). This 
enabled us to compare 26 stimulant-free, primary MDMA users with 25 stimulant-using polydrug 
MDMA users, and 56 drug-naïve healthy controls. The groups were matched for age, sex, verbal 
intelligence, years of education, depression scores, and cannabis consumption during the past half year 
(Table 2).  
The general exclusion criteria encompassed current or previous neurological disorders or head 
injuries, any clinically significant medical disease, a family history of schizophrenia or bipolar 
disorder, the prescription of drugs affecting the central nervous system, and a lifetime history of opioid 
use. Additionally, all participants who reported daily cannabis consumption were excluded. Controls 
were also excluded if they fulfilled the diagnostic criteria for any Axis-I DSM-IV psychiatric disorder 
including any form of addiction (except nicotine), or if they reported current or previous regular illegal 
drug use (except cannabis). Exclusion criteria for the MDMA groups were any acute or previous Axis-
I DSM-IV adult psychiatric disorders with the exception of MDMA, alcohol, and nicotine misuse and a 
history of depression (acute major depression was excluded). Inclusion criteria for the MDMA group 
were MDMA use of at least 100 occasions or weekly consumption during the last year, and a current 
abstinence period of less than 6 months. 
All participants were asked to abstain from illegal substances for at least three days and from alcohol 
for at least 24h prior to testing. Drug urine screenings controlled for compliance (see below). The 
Cantonal Ethics Committee of Zurich has approved the study, and all participants gave written 
informed consent. The participants were compensated for their participation with 180 Swiss Francs.  
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2.3.2 Clinical assessment 
Trained psychologists conducted the Structured Clinical Interview for Axis-I DSM-IV disorders in 
order to exclude participants with an Axis-I DSM-IV psychiatric disorder. Depressive symptoms were 
assessed with the Beck Depression Inventory (BDI) (Beck et al., 1961). Severity of ADHD symptoms 
was evaluated with the ADHD self-rating scale (ADHD-SR) corresponding to DSM-IV criteria (Rosler 
et al., 2004). Premorbid verbal intelligence was estimated with a German vocabulary test 
(Mehrfachwahl-Wortschatz-Intelligenztest) (Lehrl et al., 1995).  
 
2.3.3 Drug use assessment 
Self-reported drug use was assessed with the Interview for Psychotropic Drug Consumption 
(Quednow et al., 2004). In addition, to objectively quantify the participant’s drug use, hair samples 
were taken from the posterior vertex region of the head in order to determine the concentration of 17 
common drugs and their metabolites by liquid chromatography-tandem mass spectroscopy (Cooper et 
al., 2012). To exclude intoxication at testing, urine drug screenings were employed by semi-
quantitative enzyme multiplied immunoassay (see Supplementary Methods S1 for technical details).  
 
2.3.4 Assessment of cognitive performance 
Cognitive performance was assessed with four tests from the Cambridge Neuropsychological Test 
Automated Battery (Strauss et al., 2006): Rapid Visual Information Processing, Spatial Working 
Memory, Intra/Extra-Dimensional Set Shifting, and Paired Associates Learning. Furthermore, a 
German version of the Rey Auditory Verbal Learning Test (Helmstaedter et al., 2001) and the Letter 
Number Sequencing Task were administered (Wechsler, 1997). As previously published (Vonmoos et 
al., 2013; 2014), 15 predefined test parameters were z-transformed based on means and standard 
deviations of the control group and combined into four cognitive domains (Goldstein et al., 2004; 
Jovanovski et al., 2005; Pace-Schott et al., 2008; Woicik et al., 2009; Vonmoos et al., 2013): attention, 
working memory, declarative memory, and executive functions (see Supplementary Methods S3 for 
further details).).  
 
2.3.5 Statistical analysis 
We performed the statistical analyses with SPSS 22.0 for Windows. Demographic and drug use data 
for all groups were analyzed with Pearson’s chi-square test and analyses of variance (ANOVA). To 
investigate group differences over all groups in cognitive parameters, we performed a multiple linear 
regression with the dummy coded (zero, 1) group variables as independent variables. To compare 
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controls to the MDMA user groups, controls were chosen as the reference group, whereas for the 
comparison of the two MDMA using groups, polydrug MDMA users were coded 0 (Fig. 1 and Table 
3). To be able to assess the practical significance of cognitive performance differences between 
controls and the MDMA using groups, Cohen’s d effect sizes were calculated based on the means and 
pooled standard deviations (SD) of the two groups being compared (Cohen, 1988). Finally, we 
conducted multiple regression analyses (forced entry) to investigate the relationship between 
preselected predictors (age, sex, verbal IQ, grouping variables, BDI score and ADHD-SR score) and 
declarative memory performance. Further, multiple regression analyses were conducted over the 
MDMA users only to investigate possible factors influencing declarative memory performance in 
MDMA users; Model 1 estimated memory performance through drug use patterns covering the past 
six months (hair analyses and drug use per week) and in Model 2, estimations were based on drug use 
variables describing the duration of use or cumulative lifetime dose. Based on an à priori power 
analysis with G*Power 3.1.9.2 (Faul et al., 2007) (Linear multiple regression: Fixed model, single 
regression coefficient, f2=0.15, α= 0.05, two predictors), this study has an alpha-error probability of 
5% and a power of over 85%. 
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2.4 Results 
2.4.1 Demographic characteristics and drug use 
For demographic parameters, the groups did not differ significantly in age, verbal IQ, years of 
education, sex distribution, and depression scores (Table 2). For age, the middle 50% of all 
participants were aged between 22 and 29 years, while the youngest participant was 18 and the oldest 
47 years old. However, both MDMA groups differed from controls with regard to their ADHD-SR 
scores. For objective drug-use measures, polydrug and primary MDMA users had significantly higher 
MDMA hair drug concentrations than controls but did not differ from each other. Importantly, only 
polydrug MDMA users differed from controls in amphetamine, cocaine and ketamine hair 
concentrations, whereas primary MDMA users only showed minimal exposure to these drugs (for 
detailed hair analyses of all MDMA users see Table 1). For cannabis, amphetamine, and cocaine, 
primary MDMA users showed no significant differences regarding positive urine tests compared to 
controls, while the polydrug MDMA user group contained three cocaine-positive urine analyses. 
Primary MDMA users did not differ significantly from controls in any tobacco, alcohol, and cannabis 
measure, while polydrug MDMA users reported stronger current smoking and drinking habits. 
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Table 1: Hair analyses parameters for all groups. 
 
 Controls (n=56) Primary MDMA (n=26) Polydrug MDMA (n=25) 
MDMA    
Hair analysis pg/mgd 0.00 (0.00) 3414 (9184) 4894 (5398) 
Min / max hair value 0.00 / 0.00 32 / 48000 134 / 17500 
N > 0 0 26 25 
MDEA    
Hair analysis pg/mgd 0.00 (0.00) 7.5 (23.64) 12.96 (31.54) 
Min / max hair value 0.00 / 0.00 0 / 114 0 / 145 
N > 0 0 4 6 
MDA    
Hair analysis pg/mgd 0.00 (0.00) 90.15 (79.68) 187.96 (247.2) 
Min / max hair value 0.00 / 0.00 0 / 331 0 / 1088 
N > 0 0 25 23 
Amphetamine    
Hair analysis pg/mg 0.00 (0.00) 38.5 (63.8) 801.0 (1804) 
Min / max hair valuen 0.00 / 0.00 0 / 195 0 / 8324 
N > 0 0 9 17 
Methamphetamine    
Hair analysis pg/mgd 0.00 (0.00) 0.00 (0.00) 42.2 (152.04) 
Min / max hair value 0.00 / 0.00 0.00 / 0.00 0 / 730 
N > 0 0 0 3 
Cocaine    
Hair analysis pg/mg 0.00 (0.00) 63.8 (111.5) 3893 (5554) 
Min / max hair value 0.00 / 0.00 0 / 445 73 / 24500 
N > 0 0 10 25 
MPH    
Hair analysis pg/mgd 0.00 (0.00) 0.00 (0.00) 3.98 (17.93) 
Min / max hair value 0.00 / 0.00 0 / 0 0 / 98.5 
N > 0 0 0 2 
Morphine    
Hair analysis pg/mgd 0.00 (0.00) 0.00 (0.00) 8 (40) 
Min / max hair value 0.00 / 0.00 0 / 0 0 / 200 
N > 0 0 0 1 
Codeine    
Hair analysis pg/mgd 0.00 (0.00), n=32 0.00 (0.00), n=3 106.11 (307.24), n=9 
Min / max hair value 0.00 / 0.00 0 / 0 0 / 925 
N > 0 0 0 2 
Methadone    
Hair analysis pg/mgd 0.00 (0.00) 0.00 (0.00) 2.4 (12) 
Min / max hair value 0.00 / 0.00 0 / 0 0 / 60 
N > 0 0 0 1 
2C-B    
Hair analysis pg/mgd 0.00 (0.00), n=10 4.4 (15.4), n=25 11 (24.56), n=11 
Min / max hair value 0.00 / 0.00 0 / 63 0 / 65 
N > 0 0 2 2 
Ketamine    
Hair analysis pg/mgd 0.00 (0.00), n=10 13.26 (52.86), n=23 89.8 (127.52), n=10 
Min / max hair value 0.00 / 0.00 0 / 250 0 / 380 
N > 0 0 2 5 
 
Means, standard deviations, minimum and maximum for metabolites (pg/mg) are shown. If hair analyses were not available 
for some participants, sample size n for participants with hair analyses is shown. The cocaine metabolites benzoylecgonine, 
cocaethylene, and norcocaine are not shown. Tramadol and 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene (EDDP) are 
not shown because they were not detected.  
EDDP, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene; MDA, 3,4-Methylendioxyamphetamine; MDEA, 3,4-
Methylendioxy-N-ethylamphetmanine; MDMA, 3,4-Methylendioxy-N-methylamphetmanine; 2C-B, 2,5-dimethoxy-4-
bromphenethylamine. 
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Table 2: Demographic data and drug use (means and standard deviations) 
 
  Controls Primary MDMA Polydrug MDMA value p df 
        
n  56 26 25 
   
Age, years 25.8 (6.1) 26.6 (7.0) 26.7 (5.8) 0.25 0.78 2 
Years of school education 11.02 (1.6) 10.5 (1.8) 10.2 (1.9) 2.14 0.12 2 
Verbal intelligence 103.9 (8.2) 102.8 (8.3) 100.9 (8.3) 1.15 0.32 2 
Beck’s Depression Inventory 
score 
3.5 (3.8) 4.4 (4.8) 5.2 (4.9) 1.29 0.28 2 
ADHD-SR score  7.7 (5.1) 12.8 (8.5)** 11.76 (7.7)* 6.57 0.00 2 
ADHD (y/n)a 0/56 3/23 4/21 8.64 .01 2 
Sex (female/male) 26/30 15/11 9/16 2.41 0.30 2 
  
      
Tobacco 
      
Smoking status (y/n)b 41/15 18/8 24/1*# 6.53 0.04 2 
Cigarettes per dayb 7.3 (10.1) 5.6 (8.2) 11.8 (7.6)*# 3.30 0.04 2 
Years of use 6.0 (6.6) 4.5 (6.1) 8.8 (5.6)# 3.05 0.05 2 
  
      
Alcohol 
      
Grams per weekb 117.9 (132.0) 138.1 (119.6) 184.3 (126.5)* 2.33 0.10 2 
Years of use 8.7 (6.5) 6.6 (7.1) 8.1 (5.7) 0.99 0.37 2 
  
      
Cannabis 
      
Status (y/n)b 30/26 19/7 15/10 2.81 0.25 2 
Grams per weekb 0.44 (1.04) 0.60 (1.3) 0.67 (1.4) 0.35 0.70 2 
Years of use 3.3 (3.7) 4.4 (5.1) 4.5 (4.5) 0.90 0.41 2 
Cumulative dose (grams) 195.7 (504.6) 543.1 (962.8) 767.4 (1153)* 4.69 0.01 2 
Positive urine testing (n/y)c,d 48/7 21/5 21/4 0.60 0.74 2 
Last consumption (days) 23.1 (32.9) n=30 18.0 (36.1) n=19 12.7 (23.3) n=15 0.55 0.58 2 
Last consumption (range, days)e 3 / 111 3 / 152 3 / 91    
  
      
MDMA 
      
Tablets per weekb,f 0.00 (0.00) 0.91 (0.89)*** 0.8 (1.1)*** 23.07 0.00 2 
Years of use 0.00 (0.00) 3.4 (3.2)*** 3.6 (2.5)*** 41.64 0.00 
 
Cumulative dose (grams) 0.01 (0.04) 26.6 (32.3)*** 21.1 (30.2)*** 17.66 0.00 2 
Last consumption (days) - 25.9 (21.4) n=26 43.0 (79.1) n=20 1.12 0.30 1 
Last consumption (range, days)e - 4 / 98 4 / 365    
  
      
Amphetamine 
      
Status (y/n)b 0/56 12/14*** 18/7*** 50.00 0.00 2 
Grams per weekb 0.00 (0.00) 0.01 (0.02) 0.11 (0.14)***### 22.93 0.00 2 
Years of use 0.00 (0.00) 1.9 (3.3)*** 2.2 (2.9)*** 12.34 0.00 2 
Last consumption (days) - 34.1 (44.3) n=12 27.6 (25.2) n=18 0.26 0.61 1 
Last consumption (range, days)e - 3 / 122 5 / 91 
   
Cumulative dose (grams) 0.01 (0.03) 35.0 (129.6)* 26.0 (57.9) 2.79 0.07 2 
Positive urine testing (n/y)c,d 55/0 26/0 24/1 3.27 0.20 2 
  
      
Cocaine       
Status (y/n)b 0/56 10/16*** 22/3***### 65.05 0.00 2 
Grams per weekb 0.00 (0.00) 0.03 (0.08) 0.62 (0.72)***### 29.35 0.00 2 
Years of use 0.00 (0.00) 1.4 (3.1)* 4.9 (4.3)***### 32.36 0.00 2 
Last consumption (days)  - 33.8 (40.9) n=10,9/57 19.2 (23.5) n=22, 5/22 1.65 0.21 1 
Last consumption (range, days)e - 4 / 122 3 / 91 
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Cumulative dose (grams) 0.02 (0.05) 41.1 (162.3) 198.4 (259.1)***### 15.60 0.00 2 
Positive urine testing (n/y)c,d 55/0 26/0 22/3* 10.00 0.01 2 
       
Ketamin 
      
Status (y/n)b 0/56 2/24 6/19*** 14.40 0.00 2 
Last consumption (days) - 60.0 (17.0) n=2 244 (257.8) n=6 - - - 
Last consumption (range, days)e - 14 / 21 5 / 196    
Cumulative occasions 0.00 (0.00) 1.31 (3.98) 
 
2.86 (5.17) 
 
7.26 0.00 2 
       
       
 
Significant p-values (p<.05) are shown in bold. Statistical tests: ANOVA (all groups), χ2 test (all groups) for 
frequency data or independent t test (two groups).  
ADHD, attention-deficit/hyperactivity disorder; 
Consumption per week, duration of use, and cumulative dose are averages within the total group. 
Last consumption is an average only for persons who reported to have used the drug within the past 6 months. 
In this case, sample size (n) is shown. 
aAccording to DSM-IV criteria. 
bDuring the past 6 months. 
cFor cut-offs, see the Supplementary Methods S2. 
dOne urine sample (control) was missing. 
emin / max 
fIn 100-mg tablets. 
Post-hoc tests vs. controls: *p <.05, ** p <.01, ***p <.001; vs. primary MDMA # p <.05, ## p <.01, ### p <.001. 
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2.4.2 Cognition 
Significant regression equations with the dummy coded group variables were found for all four z-
transformed domains of attention (F(2,104)=4.591, p<.05), working memory (F(2,104)=9.584, 
p<.001), declarative memory (F(2,104)=21.187, p<.001), and executive functions (F(2,104)=7.297, 
p<.01). Group differences between controls and polydrug MDMA users were significant for all four 
domains (p<.01-.001), whereas group differences between controls and primary MDMA users only 
reached significance for working memory (p<.05) and declarative memory (p<.01) performance 
(Table 3). Effect sizes for performance differences over the four domains are shown in Figure 1. For 
polydrug MDMA vs. controls, working memory, declarative memory and executive functions reached 
large effect sizes (d=0.96, 1.21, and 0.86 respectively), while attention difficulties reached a moderate 
to large effect size (d=0.70). For the comparison of primary MDMA users and controls, only 
declarative memory impairments reached a large effect size (d=0.90), whereas working memory as 
well as executive functions displayed moderate and attention only small effect sizes. Accordingly, for 
the single cognitive parameters depicted in Figure 2, only comparisons between polydrug MDMA 
users and controls reached large effect sizes of 0.8 and higher. For primary MDMA users vs. controls, 
the largest effect sizes were found for verbal (RAVLT) and visuo-spatial (PAL) declarative memory 
measures. 
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Table 3: Cognitive parameters and domain scores. 
 
        
Controls vs. 
primary 
MDMA 
Controls vs. 
polydrug 
MDMA 
Primary vs. 
polydrug 
MDMA  
Cognitive parameters 
and domain scores 
Controls 
Primary 
MDMA 
users 
Polydrug 
MDMA 
users 
p p p 
n 56 26 25 
   Attention 0.00 (0.78) -0.19 (0.86) -0.61 (0.95) .350 .003 .074 
RAVLT Supraspan trial 1 9.6 (2.6) 8.8 (2.0) 7.9 (2.4) .182 .003 .152 
RVP Discrimination 
performance A' 
0.92 (0.04) 0.92 (0.05) 0.90 (0.05) .575 .023 .135 
RVP Total hits 18.8 (4.3) 18.3 (5.0) 16.4 (5.1) .652 .040 .162 
Working memory 0.00 (0.60) -0.36 (0.79) -0.7 (0.9) .034 .000 .064 
LNST Score 15.9 (3.1) 15.2 (2.8) 13.8 (2.1) .356 .008 .126 
SWM Total errorsa 15.6 (12.2) 17.9 (15.7) 22.8 (16.4) .498 .040 .222 
PAL First trial memory 
score 
16.9 (2.6) 15.1 (3.4) 14.2 (3.1) .011 .000 .248 
Memory 0.00 (0.76) -0.77 (0.81) -1.7 (1.8) .004 .000 .003 
RAVLT Learning 
performance 
64.8 (6.0) 60.8 (5.4) 56.4 (8.3) .011 .000 .040 
RAVLT Delayed recall 14.0 (1.5) 12.7 (1.6) 11.4 (2.5) .004 .000 .029 
RAVLT Recognition 
performance adj. 
0.91 (0.08) 0.86 (0.07) 0.8 (0.2) .038 .001 .202 
PAL Total trials adj. 7.2 (1.5) 8.3 (2.2) 10.1 (3.7) .046 .000 .014 
PAL Total errors adj. 5.6 (4.3)  9.5 (7.0) 17.8 (19.0) .106 .000 .008 
Executive functions 0.00 (0.66) -0.36 (0.96) -0.81 (1.2) .093 .000 .073 
RAVLT Recall 
consistency (%) 
94.7 (4.6) 90.6 (5.4) 86.6 (8.9) .005 .000 .033 
SWM Strategy scorea 31.7 (5.4) 30.5 (6.1) 33.7 (4.1) .378 .127 .041 
IED Total trials adj. 97.2 (49.9) 36.7 (44.6) 44.1 (54.9) .243 .060 .525 
IED Total errors adj. 26.3 (28.7) 116.4 (76.4) 131.0 (95.3) .273 .086 .581 
 
Significant p-values (p<.05) are shown in bold. Statistical tests: Multiple linear regression with the dummy coded factors 
controls vs. primary MDMA users and controls vs. polydrug MDMA users (t-test) or polydrug MDMA users vs. controls and 
polydrug MDMA users vs. primary MDMA users. 
IED, Intra-Extra Dimensional Set Shift Task; LNST, Letter Number Sequencing Task; PAL, Paired Associates Learning; 
RAVLT, Rey Auditory Verbal Learning Test; RVP, Rapid Visual Information Processing; SWM, Spatial Working Memory.  
a Data of one participant (polydrug MDMA) are missing due to a technical failure.  
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Figure 1: Cohen’s d effect sizes for primary and polydrug MDMA users vs. controls over the 
cognitive domains. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Significant dummy coded group contrasts of controls (n=56) vs. primary MDMA users (n=26): *p<.05, **p<.01; vs. 
polydrug MDMA users (n=25): ##p<.01, ###p<.001 are shown.  
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Figure 2: Cohen’s d effect sizes for primary and polydrug MDMA users vs. controls over single 
parameters. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Significant dummy coded group contrasts of controls (n=56) vs. primary MDMA users (n=26): *p<.05, **p<.01; vs. 
polydrug MDMA users (n=25): #p<.05, ##p<.01, ###p<.001 are shown.  
IED, Intra-Extra Dimensional Set Shift Task; LNST, Letter Number Sequencing Task; PAL, Paired Associates Learning; 
RAVLT, Rey Auditory Verbal Learning Test; RVP, Rapid Visual Information Processing; SWM, Spatial Working Memory.  
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2.4.3 Regression models  
To analyze potential cofactors and dose-response effects on declarative memory performance multiple 
regression analyses were performed. These analyses over all participants (n=106) for demographic 
variables (age, sex, and verbal IQ) and group contrasts revealed that being either a primary or a 
polydrug MDMA user significantly decreases the intercept of the regression equation of declarative 
memory performance (β=-.232, t=-2.76, p<.01, and β=-.508, t=-5.97, p<.001). As expected, the 
significant coefficients for age and verbal IQ were negative and positive respectively. The regression 
model was significant (R2=0.37, F5, 105=11.753, p<.001). The model only explained 2.1% more 
variance after adding the BDI and the ADHD-SR sum score in a second step (p=.183) (Supplementary 
Table S2). Neither of the two variables predicted declarative memory performance significantly 
(p=.101 and p=.130).  
The association between declarative memory performance and drug use parameters was assessed with 
two models covering either the past six month (Model 1) or lifetime substance use (Model 2) of the 
MDMA users (n=51). Model 1 contained the following variables: cannabis consumption in grams per 
week, the amount of cigarettes smoked per day, amount of alcohol consumed per week, MDMA hair 
concentration, and a grouping variable that differentiated between primary and polydrug MDMA users 
to account for stimulant use (Supplementary Table S3). None of the drug parameters predicted 
declarative memory performance. However, the grouping variable showed that polydrug substance use 
decreased the intercept (t=-1.93, p=.059, β=-.279). 
Model 2, which contained drug use parameters concerning lifetime drug consumption, revealed that – 
within MDMA users – lifetime cannabis consumption predicted declarative memory performance 
(p<.05) when duration of alcohol and nicotine use and lifetime MDMA consumption were held 
constant (Supplementary Table S4).  
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2.5 Discussion 
The aim of the study was to investigate the cognitive performance of objectively verified, primary and 
largely pure MDMA users. Detailed psychiatric diagnostics, hair toxicology, and an exact matching 
procedure minimized the influence of psychiatric comorbidities and underreported drug use. We 
demonstrated that primary and polydrug long-term MDMA users show medium to strong cognitive 
impairments in declarative memory and that, in contrast to polydrug MDMA users, primary MDMA 
users show only small and moderate impairments in the domains of attention, working memory, and 
executive functions compared with drug-naïve controls. The data of this study confirm previously 
shown memory deficits in abstinent long-term MDMA users and thus deliver evidence for declarative 
memory impairments even in largely pure recreational MDMA users with no or minimal stimulant co-
use.  
 
In line with previous meta-analyses (Kalechstein et al., 2007; Laws and Kokkalis, 2007; Rogers et al., 
2009), our data show that the strongest impairments have to be expected in declarative memory 
functions after repeated MDMA consumption, which confirms our hypothesis. Task-specifically, 
decreased delayed verbal memory performance (RAVLT) can be considered the “main symptom” of 
MDMA misuse as the variable delayed recall has been repeatedly shown to differentiate between 
MDMA users and controls (Reneman et al., 2000; Fox et al., 2001; Quednow et al., 2006) and 
revealed the strongest effect size in this study for polydrug MDMA users as well as for primary 
MDMA users. In line with previous findings (Laws and Kokkalis, 2007), effect sizes for verbal 
memory deficits were larger than for visual memory deficits in MDMA users. Regarding the PAL 
measures, our data are in accordance with previous studies showing that polydrug MDMA users 
required more trials to complete the task compared to polydrug controls (Fox et al., 2002). Taken 
together, the individual variables of our declarative memory domain indicate moderate to large 
impairments (d=0.62-1.1) in visual, spatial and verbal learning and recognition processes.  
Regarding working memory deficits, the primary MDMA users performed worse than controls on the 
domain level only with a medium effect size (d=0.52), whereas polydrug MDMA users showed strong 
working memory impairments (d=0.96). This discrepancy in performance may explain the 
inconsistencies in previous findings and underline the additional detrimental effect of stimulant use on 
working memory (Vonmoos et al., 2013; 2014). Interestingly, primary MDMA users did not differ 
substantially from controls in two out of three measures for working memory, LNST score and total 
errors in the SWM task. Both measures are widely accepted measures for working memory 
performance (Morris et al., 1988; Crowe, 2000) and have previously been linked to MDMA-induced 
deficits (Fox et al., 2002; 2005). Our data do not replicate these findings for largely pure MDMA users 
but support our hypothesis that working memory deficits in polydrug MDMA users are likely 
stimulant-driven, and consequently, that past findings may be explained by undetected stimulant co-
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consumption. It is noteworthy that – although our working memory domain differentiated significantly 
between controls and primary MDMA users – only the underlying first trial memory score (PAL) 
reached significance. This variable was viewed as a measure for passive storage ability and has shown 
to correlate stronger with verbal than with non-verbal memory parameters, probably because subjects 
verbalize the patterns and/or places which have to be remembered (Torgersen et al., 2012). In the 
context of Fox et al.’s (2001) suggestion that verbal learning problems in MDMA users are associated 
with storage and retrieval problems, and the finding that MDMA use affects verbal memory more 
strongly than visual memory, it can be argued that working memory performance between primary 
MDMA users and controls might in sum be less impaired then our working memory domain suggests 
at a first glance. Alternatively, the moderate working memory impairment displayed by our primary 
MDMA user group might be a result of past stimulant consumption, which may have occurred before 
the time span captured by the hair analyses. This idea is supported by a significant negative correlation 
between working memory performance and self-reported lifetime cocaine consumption across all 
MDMA users (r(49)=-.40, p<.01).  
For primary MDMA users, we did not find any significant results in the domains of executive 
functions and attention except for the RAVLT parameter recall consistency, which contrasts with 
previous studies that found executive function and decision-making impairments in MDMA users 
(Fisk et al., 2004; Montgomery et al., 2005; Quednow et al., 2007; Fisk and Montgomery, 2009; 
Roberts et al., 2016b). On the other hand, Montgomery et al. (2005) – who investigated the executive 
functions specifically – found no impairments in MDMA users compared to controls in switching, 
which is – besides updating – tested by the Intra-Extra Dimensional Set Shift Task (IED) applied in 
the present study. In line with Montgomery et al. (2005) we did not find changes in the IED 
performance in primary MDMA users. Interestingly, the only variable assessing executive functions 
that reached significance (recall consistency, RAVLT) strongly involves verbal memory in contrast to 
the other, non-significant variables involving visual memory processes. As mentioned before, results 
vary regarding attentional performance of MDMA users, which is also reflected in our results; in all 
three parameters measuring attention, the polydrug MDMA users performed significantly worse than 
controls with moderate effect sizes, whereas primary MDMA users did not differ substantially from 
controls. These results are in line with previous research as 1) stimulant users were shown to perform 
worse than drug-naïve controls in an equally created attention domain (Vonmoos et al., 2013), and 2) 
as basic attentional and executive functions are generally unaffected in MDMA users compared to 
polydrug or cannabis using control groups (Parrott, 2001; Medina et al., 2005; Rogers et al., 2009). 
Interestingly, in contrast to our polydrug MDMA users, largely pure cocaine users did not differ from 
stimulant-naïve controls in the RAVLT supraspan in a previous study from our lab (Vonmoos et al., 
2013). Future research should therefore investigate possible interaction effects of MDMA and 
stimulant consumption more in depth, especially because animal studies revealed that the 
simultaneous administration of MDMA (or MDMA analogues) and a prodopaminergic agent leads to 
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a potentiation of the serotonin neurotoxicity of MDMA (Johnson et al., 1991; Johnson and Nichols, 
1991; Schmidt et al., 1991; Clemens et al., 2005).  
 
The results of our regression analysis for demographic variables support the notion of declarative 
memory deficits in abstinent primary MDMA users, as group contrasts remained significant even 
when sex, age, and verbal IQ were held constant. By adding the BDI and ADHD-SR sum core, the 
model only improved marginally. We have previously investigated the effects of depression and 
ADHD symptoms on cognitive performance in cocaine users and found that both factors, ADHD and 
depression scores, were associated with worse cognitive performance in cocaine users (Vonmoos et 
al., 2013; Wunderli et al., 2016). We therefore expected to find significant contributions of these two 
variables in the regression model again. However, probably due to the relative small variance in BDI 
and ADHS-SR scores and the matching process (exclusion of psychiatric disorders), declarative 
memory was not significantly predicted through these two measures.  
Model 1, which predicted declarative memory performance through drug use parameters covering the 
past six months, revealed no significant associations except for the grouping variable that 
distinguished between primary and polydrug MDMA users. Although this grouping variable only 
predicted declarative memory performance by trend (p=.059), the importance of stimulant co-
consumption is emphasized by the fact that polydrug MDMA users displayed higher – although none 
significantly higher – mean values in all of the other predictors. 
In Model 2, declarative memory performance was aimed to be predicted by factors covering 
cumulative lifetime drug use estimates. Although the whole model predicted declarative memory 
performance by trend only, it revealed that the estimated lifetime dose of cannabis was negatively 
associated with memory performance. Additionally, the grouping variable still predicted memory 
performance with constant drug factors by trend. It was postulated previously that cognitive deficits in 
MDMA users can be explained by cannabis co-use alone (Croft et al., 2001). Our data do not support 
this assumption because the two user groups still differ in declarative memory performance when the 
effect of cannabis consumption is held constant. This finding is therefore in line with previous studies 
demonstrating memory deficits in MDMA users, even when concomitant cannabis use was introduced 
as a covariate or when MDMA users were compared to cannabis using controls (Fox et al., 2001; 
Quednow et al., 2006). However, our results support the notion that cannabis is an important confound 
when cognitive performance is measured in MDMA users (Croft et al., 2001; Simon and Mattick, 
2002), although the cannabis use intensity was relatively low in our sample.  
Finally, in both models, severity of MDMA consumption did not predict declarative memory 
performance (MDMA hair concentration and lifetime dose). Previous literature is inconclusive about 
the correlation between MDMA dose and strength of impairments. Many researchers reported dose-
related impairments in MDMA users (Bolla et al., 1998; Gouzoulis-Mayfrank et al., 2000; 
Montgomery et al., 2005; Quednow et al., 2006). These findings were usually interpreted as evidence 
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for selective, neurotoxic effects on the 5-HT system (Parrott, 2002; Gouzoulis-Mayfrank et al., 2003; 
Quednow et al., 2004; Quednow et al., 2006). On the other hand, Laws and Kokkalis (2007) found no 
continuous relationship of lifetime MDMA consumption of MDMA and memory measures in their 
meta-analysis and therefore proposed a rather stepwise relationship between MDMA use and memory 
decline. This explanation is in line with a recent, longitudinal study that only found marginally 
significant changes in recall measures in stimulant-using polydrug MDMA users over a 2 year period 
(Wagner et al., 2015). Because neither MDMA hair concentrations nor self-reported amount of 
lifetime MDMA consumption significantly predicted memory performance, our data support this 
model of a stepwise relationship between MDMA use and memory decline. Moreover, also duration of 
abstinence did not predict memory performance in our sample (β=.010, t=0.70, p=.945). An alternative 
explanation of these discrepancies may lie in the variability of the purity of MDMA tablets potentially 
leading to different results across studies (Morgan, 1999; Parrott, 2004). In fact, recent analyses in the 
context of the Swiss Drug Checking program showed that only 7.1% of the ecstasy samples (n=210) 
tested in 2016 contained psychoactive substances other than MDMA (see 
http://www.saferparty.ch/125.html). 
This study has some limitations. First, human MDMA research practice was criticized for applying 
unreliable self-reported drug assessments (Cole, 2014). Although we objectively quantified 
participants drug use via hair analyses, we had to rely on participants self-reports for alcohol, nicotine, 
and cannabis consumption. Obviously, in a sample in which memory deficits can be expected, self-
reported drug assessment might be less reliable. Nonetheless, we aimed to minimize the influence of 
these drugs by matching the groups accordingly. Second, there is the possibility that cognitive 
differences are based on pre-existing differences and that predispositions are responsible for drug use 
and cognitive impairments. This limitation can be controlled by adding a polydrug control group. 
However, the present investigation is a cross-sectional study that is not suitable to differentiate 
between predisposing factors and drug-induced alterations. 
 
Taken together, our data suggest that the combined use of MDMA and stimulants is associated with a 
strongly increased risk for cognitive impairments compared to primary MDMA consumption and that 
the pronounced working memory and executive function impairments in polydrug MDMA users are 
likely driven by stimulant co-use. However, primary MDMA users showed robust and strong 
alterations of declarative long-term memory. The considerable performance difference of primary vs. 
polydrug MDMA users together with the finding that cannabis additionally impairs memory 
performance in MDMA users highlights the need for objective group assessments in human MDMA 
research. Future research should therefore distinguish between stimulant using and primary MDMA 
users while the influence of other drugs of abuse but especially cannabis consumption should be either 
excluded or controlled for by matching or an additional cannabis-only user group. 
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2.7 Supplementary material 
2.7.1 Methods 
Methods S1: Urine and hair toxicology 
Urine toxicology analyses comprised the following substances: tetrahydrocannabinol, cocaine, 
amphetamines, benzodiazepines, opioids, and methadone and were assessed by a semi-quantitative 
enzyme multiplied immunoassay method using a Dimension RXL Max (Siemens, Erlangen, 
Germany). For the detection of illegal drug use, the following cut-offs have been applied (Bush, 
2008): Cannabis, 50 ng/ml; cocaine, 150 ng/ml; and amphetamines, 500 ng/ml.  
To objectively characterize drug use over the last six months, hair samples were collected and 
analyzed with liquid chromatography-tandem mass spectrometry (LC-MS/MS). The proximal hair 
segment of a length of up to 6 cm was examined. The following 17 compounds were assessed: 
cocaine, benzoylecgonine, cocaethylene, norcocaine, amphetamine, methamphetamine, MDMA, 
MDEA, MDA, morphine, codeine, methadone, EDDP (primary methadone metabolite, 2-ethylidene-
1,5-dimethyl-3,3-diphenylpyrrolidene), tramadol, 2C-B, ketamine, and methylphenidate.  
For our routine protocol for drugs of abuse analysis a three-step washing procedure with water (2 
minutes shaking, 15ml), acetone (2min., 10ml) and finally hexane (2min., 10ml) of hair was 
performed. Then the hair samples were dried at ambient temperatures, cut into small snippets and 
extracted in two steps, first with methanol (5ml, 16 hours, ultrasonication) and a second step with 3 ml 
MeOH acidified with 50 µL hydrochloric acid 33 % (3 hours, ultrasonication). The extracts were dried 
and the residue reconstituted with 50 µL MeOH and 500 µL 0.2 mM ammonium formate (analytical 
grade) in water. As internal standards deuterated standards of the following compounds were used, 
added as mixture of the following compounds: cocaine-d3, benzoylecgonine-d3, ethylcocaine-d3, 
morphine-d3, MAM-d3, codeine-d3, dihydrocodeine-d3, amphetamine-d6, methamphetamine-d9, 
MDMA-d5. MDEA-d6, MDA-d5, methadone-d9, EDDP-d3, methylphenidate-d9, tramadol-d3, 
oxycodone-d3, and ephedrine-d3. All deuterated standards were from ReseaChem (Burgdorf, 
Switzerland), the solvents for washing and extraction were of analysis grade and obtained from Merck 
(Darmstadt, Germany); LC-solvents were of HPLC grade and were obtained from Sigma Aldrich 
(Buchs, Switzerland). 
The LC-MS/MS apparatus was an ABSciex QTrap 3200 (Analyst software Version 1.5, Turbo V ion 
source operated in the ESI mode, gas 1, nitrogen (50 psi); gas 2, nitrogen (60 psi); ion spray voltage, 
3500V; ion source temperature, 450°C; curtain gas, nitrogen (20 psi) collision gas, medium), with a 
Shimadzu Prominence LC-system (Shimadzu CBM 20 A controller, two Shimadzu LC 20 AD pumps 
including a degasser, a Shimadzu SIL 20 AC autosampler and a Shimadzu CTO 20 AC column oven, 
Shimadzu, Duisburg, Germany). Gradient elution was performed on a separation column (Synergi 4µ 
POLAR-RP 80A, 150x2.0 with a POLAR-RP 4x2.0 Security Guard Cartridge, (Phenomenex, 
Aschaffenburg, Germany). The mobile phase consisted of 1mM ammonium formate buffer adjusted to 
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pH 3,5 with formic acid (eluent A) and acetonitrile containing 1mM ammonium formate and 1 mM 
formic acid (eluent B). The analysis was performed in MRM mode with two transitions per analyte 
and one transition for each deuterated internal standard, respectively. According to the Society of Hair 
Testing (Society of Hair, 2004), the following cut-offs have been applied: cocaine, 500 pg/mg; 
amphetamine, 200 pg/mg; and MDMA, 200 pg/mg. 
 
Methods S2: Construction of cognitive domain scores 
Fifteen predefined main cognitive test parameters were z-transformed on the basis of means and 
standard deviations of the control group as published before (Vonmoos et al., 2013). If necessary, test 
scores were reversed so that high scores always indicated a better cognitive performance. These 
parameters were reduced to the four cognitive domains attention, working memory, declarative 
memory, and executive function. Furthermore, these four z-scored domains were equally integrated 
into a broad global cognitive index (GCI).  
Attention: To assess attentional capacity, we focused primarily on sustained attention by including the 
two Rapid Visual Information Processing (RVP) parameters discrimination performance A’ and total 
of hits (Jones et al., 1992). In order to diversify this domain we added the Ray Auditory Verbal 
Learning Test (RAVLT) parameter trial 1, a supraspan measure with a large attentional component 
(Lezak et al., 2004).  
Working Memory: The Spatial Working Memory (SWM) parameter number of total errors tested the 
capability to retain spatial information and to manipulate remembered items in working memory 
(Morris et al., 1988). The Letter Number Sequencing Test (LNST) measured the verbal working 
memory by summing up the number of correct responses (Wechsler, 1997). The third parameter was 
the number of correctly located patterns after the first presentation, a Paired Associates Learning 
(PAL) parameter measuring primarily a visual working memory component (Sahakian et al., 1988). 
Declarative memory: The RAVLT was administered to assess the verbal declarative memory 
performance (Helmstaedter et al., 2001). Performance was measured by the parameters learning 
performance (∑trials 1-5), delayed recall (trial 7), and an adjusted recognition performance (p(A)) 
(Helmstaedter et al., 2001). To capture the visual declarative memory, we used the two PAL 
parameters: adjusted total of errors and adjusted total of trials (Sahakian et al., 1988). 
Executive Functions: The Intra/Extra-Dimensional Set Shifting Task (IED) assessed visual 
discrimination, attentional set formation, maintenance, shifting, and flexibility (Downes et al., 1989). 
The considered test parameters were the total of errors and trials adjusted to the amount of completed 
stages. Hereby, we added the SWM strategy score assessing the applied heuristic strategies (Morris et 
al., 1988), and the RAVLT recall consistency, a parameter impaired in patients with prefrontal lesions 
(Jokeit et al., 1997; Alexander et al., 2003; Benedict et al., 2005) and related with measures of 
executive functions (Beebe et al., 2000). 
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2.7.2 Results 
Table S1. Hair analyses results (concentratin calues in pg/mg) and MDMA group allocation. 
 
 
For each participant, the amount of metabolites per substance (pg/mg) and the group are shown. The cocaine metabolites 
benzoylecgonine, cocaethylene, and norcocaine are not shown. Tramadol is not shown because it was not detected. Reasons for 
polydrug MDMA classification are shown in bold. 
To be included into the primary MDMA group, hair samples had to reveal a cocaine value <500pg/mg and an amphetamine value 
<200pg/mg (Cooper et al., 2012). 
1 analyzed hair length from scalp in cm.  
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EDDP, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene; MDA, 3,4-Methylendioxyamphetamine; MDEA, 3,4-
Methylendioxy-N-ethylamphetmanine; MDMA, 3,4-Methylendioxy-N-methylamphetmanine; n.a., not available; 2C-B, 2,5-
dimethoxy-4-bromphenethylamine.  
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Table S2. Multiple Regression analysis for demographic variables, group contrasts and 
psychopathology predicting memory performance 
 
  B SE B β 
Step 2 
   
Constant -.191 .229 
 
primary MDMA vs. Controls -.828 .271 -.270** 
poly MDMA vs. Controls -1.603 .268 -.523*** 
Sex -.041 .214 -.016 
Age -.041 .018 -.194* 
Verbal IQ .037 .013 .232** 
BDI sum score -.045 .027 -.150 
ADHD sum score .028 .018 .148 
 
Dependent variable: declarative memory performance (z-score). 
N = 106 (26 primary MDMA users, 25 poly MDMA users, and 56 controls).  
R2 = .37 and F = 11.753 (p<.001) for Step 1, ΔR2 = .021 and ΔF = 1.726 (p = .183) for Step 2. 
The data met the assumption of independent errors (Durbin-Watson value = 2.13). 
ADHD = Attention Deficit / Hyperactivity Disorder, ADHD sum score = Sum of Items 1 to 18, B = regression coefficient, β 
= standardized Beta, BDI = Beck’s Depression Inventory, SE B = standard error. 
Age is centered at the overall mean age (26.21 years) and verbal IQ is centered at 100 IQ points. Females were coded with 1 
and males with 0 for the sex variable.  
* p <.05, ** p <.01, *** p <.001 
 
 
Table S3. Multiple regression analysis for drug use variables covering consumption over the past half 
year predicting memory performance 
 
  B SE B β 
Constant 11.415 6.388 
 primary MDMA vs. poly MDMA -.810 .419 -.279(*) 
Cannabis (g/week) -.232 .152 -.208 
Nicotine (cigarettes per day) -.039 .026 -.224 
Alcohol (g/week) .001 .002 .108 
MDMA hair concentration (pg/mg) .000 .000 .213 
 
Dependent variable: declarative memory performance (z-score). 
N = 51 (26 primary MDMA users, 25 poly MDMA users).  
R2 = .21 and F = 2.372 (p=.054). 
The data met the assumption of independent errors (Durbin-Watson value = 2.55). 
B = regression coefficient, β = standardized Beta, g/week = grams per week, pg/mg = picogram per milligram, SE B 
= standard error. 
Poly MDMA users were coded with 1 and primary MDMA users with 0 for the group comparison.  
(*) p =.059 
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Table S4. Multiple regression analysis for drug use variables covering 
consumption over the lifetime predicting memory performance 
 
  B SE B β 
Constant 11.232 6.498 
 primary MDMA vs. poly MDMA -.773 .423 -.266(*) 
Alcohol (years of use) -.018 .035 -.080 
Nicotine (years of use) -.016 .039 -.067 
Cannabis lifetime dose (g) -.000 .000 -.271* 
MDMA lifetime dose (tablets1) -.000 .001 -.011 
 
Dependent variable: declarative memory performance (z-score). 
N = 51 (26 primary MDMA users, 25 poly MDMA users).  
R2 = .19 and F = 2.103 (p=.083). 
The data met the assumption of independent errors (Durbin-Watson value = 2.40). 
B = regression coefficient, β = standardized Beta, g = grams, SE B = standard error. 
1 tablets à 100mg 
Poly MDMA users were coded with 1 and primary MDMA users with 0 for the group 
comparison.  
(*) p =.075, *p=.052 
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3.1 Abstract 
Background. The empathogen 3,4-methylenedioxymethamphetamine (MDMA) is the prototypical 
prosocial club drug inducing emotional openness to others. It has recently been shown that acutely 
applied MDMA in fact enhances emotional empathy and prosocial behavior, while it simultaneously 
decreases cognitive empathy. However, the long-term effects of MDMA use on socio-cognitive 
functions and social interactions have not been investigated yet. Therefore, we examined emotional 
and cognitive empathy, social decision-making, and oxytocin plasma levels in chronic MDMA users. 
 
Methods. We tested 38 regular but recently abstinent MDMA users and 56 MDMA-naïve controls 
with the Movie for the Assessment of Social Cognition (MASC), the Multifaceted Empathy Test 
(MET), the Distribution Game and the Dictator Game. Drug use was objectively quantified by 6-
month hair analyses. Furthermore, oxytocin plasma levels were determined in smaller subgroups (24 
MDMA users, 9 controls). 
 
Results. MDMA users showed superior cognitive empathy compared with controls in the MET 
(Cohen’s d=.39) and in the MASC (d=.50), but they did not differ from controls in emotional 
empathy. Moreover, MDMA users acted less self-serving in the Distribution Game. However, within 
MDMA users, multiple regression analyses showed that higher MDMA concentrations in hair were 
associated with lower cognitive empathy (βMDMA=-.34, t=-2.12, p<.05). Oxytocin plasma 
concentrations did not significantly differ between both groups. 
 
Conclusions. We conclude that people with high cognitive empathy abilities and pronounced social 
motivations might be more prone to MDMA consumption. In contrast, long-term MDMA use might 
nevertheless have a detrimental effect on cognitive empathy capacity. 
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3.2 Introduction 
With an estimated 19.4 million past-year users, 3,4-methylenedioxymethamphetamine (MDMA, 
“ecstasy”) remains one of the most used illicit drugs worldwide (United Nations Office on Drugs and 
Crime, 2016). MDMA is a synthetic substituted amphetamine derivate that blocks and reverses 
monoamine transporters leading to a rapid release of serotonin (5-HT) and noradrenalin and to a lesser 
extend dopamine (Rudnick and Wall, 1992; Kalant, 2001). As its main positive subjective effects are 
enhanced empathy, increased prosocial feelings, and a general sense of well-being, MDMA is 
regarded as the prototypical prosocial club drug (Vollenweider et al., 1998; Kamilar-Britt and Bedi, 
2015). Consequently, in an international survey on drug users, MDMA was ranked highest in the 
condition of sociability (Morgan et al., 2013).  
In animals, the acute effects of MDMA on social behavior have been researched extensively, whereby 
“adjacent lying” and “friendly following” were consistently reported to be increased in rats (Ando et 
al., 2006; Thompson et al., 2009). Together with decreased aggression and elevated social reward, 
literature consistently suggests a prosocial effect profile of MDMA in rodents (Kamilar-Britt and Bedi, 
2015). Recently, social cognition has been broadly investigated in MDMA-challenge studies 
conducted on healthy human volunteers mostly focusing on measures of empathy. The concept of 
empathy has frequently been conceptualized as entailing cognitive and emotional components. 
Cognitive empathy, which comprises inferring or discriminating emotions of others together with 
Theory-of-Mind (ToM), which additionally implicates the ability to deduce the perspective of others, 
describes the ability to decode and understand another person’s mental state (Baron-Cohen and 
Wheelwright, 2004; Blair, 2005) on a mere cognitive level without considering the persons emotional 
response. On the other side, emotional empathy is defined as the compassion or the empathizing with 
the emotions of others (Blair, 2005).  
Regarding cognitive empathy, acute MDMA intake has repeatedly been shown to reduce the 
identification of negative emotional stimuli (Bedi et al., 2010; Hysek et al., 2012; Hysek et al., 2014b; 
Hysek et al., 2014a; Kirkpatrick et al., 2014) and one study additionally found an increased 
recognition of positive emotional stimuli (Hysek et al., 2012). These valence-dependent acute MDMA 
effects were – to our knowledge – exclusively found in the Face Emotion Recognition Task (FERT) 
(Bedi et al., 2010; Hysek et al., 2014b) and the Reading the Mind in the Eyes Test (RMET) (Hysek et 
al., 2012). In two other well-established social cognition tasks, namely the Movie for the Assessment of 
Social Cognition (MASC) and the Multifaceted Empathy Test (MET), cognitive empathy performance 
was not affected by acute MDMA intake (Kuypers et al., 2017). By contrast, emotional empathy 
ratings – driven by enhanced responses to emotionally positively charged stimuli – was shown to be 
increased in the MET under the acute influence of MDMA (Hysek et al., 2014b; Schmid et al., 2014). 
In summary, research on empathy performance suggests that acute MDMA intake decreases cognitive 
empathy but enhances emotional empathy (Kamilar-Britt and Bedi, 2015), even though these findings 
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are limited to specific tasks. Interestingly, these acute prosocial effects of MDMA have been linked to 
central oxytocin (OXT) release, as several studies have found dose-dependent increases in blood 
plasma OXT levels right after MDMA administration (Wolff et al., 2006; Dumont et al., 2009; Hysek 
et al., 2012; Schmid et al., 2014). This increase in plasma OXT levels was shown to correlate with 
increased prosocial feelings in humans (Dumont et al., 2009).  
Interestingly, no study has investigated social cognition in abstinent, long-term MDMA users to date. 
Thus, we measured cognitive and emotional empathy of relatively pure MDMA users and drug-naïve 
healthy controls with the MASC and the MET. To measure social decision-making, we additionally 
applied the Distribution Game and the Dictator Game (Charness and Rabin, 2002; Engelmann and 
Strobel, 2004). Given that acutely applied MDMA increases plasma levels of OXT (Dumont et al., 
2009; Hysek et al., 2012) and that a former animal study documented lasting depletion of brain OXT 
after long-term MDMA administration (van Nieuwenhuijzen et al., 2010), we additionally investigated 
blood plasma OXT levels in a subsample of our participants. Finally, as a special feature of our study, 
we objectively determined drug use through quantitative hair analyses for several reasons. First, 
MDMA users often co-use other drugs (Schifano et al., 1998; Curran, 2000) and previous MDMA 
research has been criticized for measuring drug consumption only via self-reports (Cole, 2014). 
Second, drug users might be motivated to give a biased self-report or simply over- or underestimate 
their own consumption because of consistently shown memory alterations (Magura and Kang, 1996; 
Quednow et al., 2006; Wunderli et al., 2017).  
 
Because MDMA has been shown to impair OXT neurotransmission in rats when given chronically 
(van Nieuwenhuijzen et al., 2010) and because OXT and emotional empathy seem to be functionally 
linked (Thompson et al., 2007; Kirkpatrick et al., 2014), we hypothesized that chronic MDMA users 
show a deficit in emotional empathy and display lowered plasma levels of OXT. Alternatively, such 
deficits could also be preexistent given that the main motivator for MDMA use is to enhance prosocial 
feelings like feeling closer to other people (Morgan et al., 2013) and to increase emotional empathy 
(Hysek et al., 2014b). Thus, recreational MDMA users might compensate (or self-medicate) a deficit 
in emotional empathy and lower OXT levels by their drug intake. Lastly, we expected higher MDMA 
use to be associated with lower cognitive empathy as it was shown by an inverse correlation between 
lifetime MDMA use and RMET performance in one of our previous studies (Preller et al., 2014).  
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3.3 Method 
3.3.1 Participants 
Within the context of the Zurich Cocaine Cognition Study (ZuCo2St) (Vonmoos et al., 2013b; 
Quednow, 2016), we recruited 53 long-term MDMA users and 56 MDMA-naïve healthy controls by 
means of online media and flyer advertisements. Candidates underwent a standardized telephone 
screening to assess their study eligibility prior to testing. All tested participants were aged between 18 
and 60 years and had sufficient German language skills. We only included MDMA users whose self-
reported drug use was confirmed by hair analyses and whose MDMA hair concentration values 
exceeded their cocaine and amphetamine concentrations – the most common concomitant drugs in our 
sample. Primary stimulant users with only a co-consumption of MDMA were thus excluded, as 
stimulants have been shown to strongly affect social cognition (Quednow, 2017). Furthermore, 
because of deficient/missing hair samples, two MDMA users were excluded. Following this 
procedure, 38 participants were identified as MDMA-preferring users and included in the analyses 
(see Supplementary Table S1 for detailed hair analyses). The MDMA group was matched with 56 
MDMA-naïve healthy controls with regard to age, sex, verbal intelligence, years of education, 
depression scores, and weekly cannabis consumption (Table 1).  
Inclusion criteria for the drug using group were MDMA as the primary drug, MDMA use of at least 
100 standard doses (one MDMA standard dose corresponds to 100mg crystalline MDMA or one 
ecstasy pill) or weekly consumption during the last year (>50 occasions), and a current abstinence 
period of less than six months. Exclusion criteria for the MDMA groups were any acute or previous 
Axis-I DSM-IV adult psychiatric disorders with the exception of MDMA, alcohol, and nicotine abuse 
and a history of depression (acute major depression was excluded). The general exclusion criteria 
encompassed current or previous neurological disorders or head injuries, any clinically significant 
medical disease, a family history of schizophrenia or bipolar disorder, the use of any medication 
affecting the central nervous system, and a lifetime history of opioid use. Additionally, all participants 
who reported daily (or more frequent) cannabis consumption were excluded. Controls were also 
excluded if they fulfilled the diagnostic criteria for any Axis-I DSM-IV psychiatric disorder, including 
any form of substance use disorder (except nicotine and cannabis), or any other current or previous 
regular illegal drug use.  
All participants were asked to abstain from illegal substances for at least three days and from alcohol 
for at least 24h prior to testing. Drug urine screenings were employed to control for compliance with 
the abstinence period (see Table 1). The study was approved by the Cantonal Ethics Committee of 
Zurich. All participants gave written informed consent and were compensated for their participation. 
Both, MDMA users and MDMA-naïve healthy controls were already published in Wunderli et al. 
(2017), however polydrug users with hair concentrations of stimulants (e.g., cocaine and 
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amphetamine) exceeding the values of MDMA were excluded from the present analysis. Moreover, 
the present MDMA user sample did not overlap with the samples of previous publications from the 
ZuCo2St including cocaine users and stimulant-naïve controls (e.g., Preller et al., 2013; Vonmoos et 
al., 2013b; Hulka et al., 2014; Preller et al., 2014). However, about 75% of the present control group 
has been reported in these previous publications but all participants from the ZuCo2St and the present 
study were investigated with the same procedure in the same environment and by the same study team. 
 
3.3.2 Clinical assessment 
Trained psychologists conducted the Structured Clinical Interview for Axis-I DSM-IV disorders (SCID 
I). Depressive symptoms were assessed with the Beck Depression Inventory (BDI) (Beck et al., 1961) 
because depression might impact social cognition (Schreiter et al., 2013) and ADHD symptoms with 
the ADHD Self-Rating Scale (ADHD-SR) corresponding to DSM-IV criteria (Rosler et al., 2004) given 
that ADHD and drug use were shown to mutually amplify ToM deficits (Wunderli et al., 2016). 
Premorbid verbal intelligence (verbal IQ) was estimated with a German vocabulary test 
(Mehrfachwahl-Wortschatz-Intelligenztest) (Lehrl et al., 1995). To assess the personality structure of 
our sample, we further applied the Barratt Impulsiveness Scale (BIS-11) (Patton et al., 1995) and the 
Temperament Character Inventory (TCI) (Cloninger, 1994). 
 
3.3.3 Drug use assessment 
Self-reported drug use was assessed with the Interview for Psychotropic Drug Consumption 
(Quednow et al., 2004). In addition, to objectively quantify the severity of participant’s drug use 
during the past months, hair samples were taken from the posterior vertex region of the head in order 
to determine the concentration of 17 common drugs and their metabolites by liquid chromatography-
tandem mass spectroscopy (LC-MS/MS). To exclude acute intoxication at testing sessions, urine drug 
screenings were employed by semi-quantitative enzyme multiplied immunoassays (for technical 
details see Supplementary Methods S1). 
 
3.3.4 Assessment of empathy and social decision-making 
MET 
The MET is a computer-based test that consists of 40 pictures of people in emotionally charged 
situations (Dziobek et al., 2008). Based on the idea that empathy is a multidimensional construct 
consisting of cognitive and emotional empathy (Davis, 1983), the MET requires the participant to 
deduce the mental state of the depicted person by choosing which out of four words best describes the 
person’s mental state (cognitive empathy) on one side, and to indicate his/her empathic concern 
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(explicit emotional empathy) and arousing rate (implicit emotional empathy) on a rating scale (1-9). 
To avoid multiple testing, we combined (summed up) the implicit and explicit emotional empathy 
measures (for both negative and positive stimuli) from the MET to an overall emotional empathy score 
(EES) (see Table 2). 
 
MASC 
The MASC was developed with the aim to operationalize social cognition as close to real life as 
possible and therefore consists of a 15min video that shows four characters spending an evening 
together. The video stops 45 times and questions about the characters’ feelings, thoughts, and 
intentions are asked (Dziobek et al., 2006). For each question, four different answers are presented 
whereof one answer represents the correct answer. The wrong answers represent three different 
mistakes: 1) Instead of mentalizing, the subject explained the situation by physical causation (no 
ToM), 2) the subject undermentalized (less ToM), and 3) the subject overmentalized (too much ToM). 
The correct number of answers is the main outcome measure of the MASC. Additionally, we built the 
cognitive empathy domain score (CES) by averaging the MET cognitive empathy score and the 
MASC sum score after they were z-transformed on the means and standard deviations of the control 
group to a combined measure of cognitive empathy. 
 
Distribution Game and Dictator Game 
The Distribution Game and the Dictator Game have been described in detail before (Hulka et al., 
2014). Notably, in these two monetary distribution games, the participants actually had the chance to 
gain real money (0.25 Swiss francs per 1 point). In brief, the Distribution Game involves two players. 
The participant – every time in the position of player A – is requested to choose one out of 10 possible 
point distributions. In the first distribution, both players receive the same amount of 25 points, which 
represents the only completely fair distribution. In the most unfair distribution, player A receives 40 
points (Payoff A) and player B only one point (Payoff B). 
The Dictator Game, which always followed the Distribution Game, involved the same two players, 
whereby player A was asked to distribute 50 points among himself (Payoff A) and player B (Payoff 
B). In accordance with a previously published paper from the ZuCo2St (Hulka et al., 2014), we z-
transformed the measures of the Distribution and Dictator Game on the means and standard deviation 
of the control group and equally integrated them into the composite Payoff A and Payoff B scores. 
For both games, we analyzed Payoff A as the main dependent variable.  
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3.3.5 Assessment of blood plasma OXT levels 
The blood was collected in 5 ml BD Vacutainer K2EDTA tubes (Vacutainer Systems, becton 
Dickinson, Plymouth, UK) and immediately mounted on ice. Right after blood collection, the samples 
were centrifuged at 4000 rpm for 10 min at 4°C to separate the plasma. After pipetting the plasma, it 
was stored at -80°C until it was analyzed according to procedures employed in previous studies 
(Neumann et al., 2013; Bosch et al., 2015). 
 
3.3.6 Statistical analysis 
We performed the statistical analyses with SPSS 23.0 for Windows. Quantitative data were either 
analyzed by means of Students t-tests (only demographic data), Mann-Whitney tests, or two-way 
analyses of covariance (ANCOVA). Frequency data were analyzed by means of Pearson’s chi-square 
tests. We used an alpha level of .05 for all statistical tests. In the ANCOVAs applied to compare 
empathy between MDMA users and controls, we introduced group and sex as fixed factors, and verbal 
IQ as a covariate because it was consistently shown that men are less empathic that women 
(Fukushima and Hiraki, 2006; Knickmeyer et al., 2006; Singer et al., 2006; Rueckert and Naybar, 
2008) and because verbal IQ has been proposed to be linked to empathy measures before (Lawrence et 
al., 2004). Analyzing social decision-making with ANCOVAs, sex was used as a second covariate to 
verbal IQ given that age is correlated with prosocial behavior (Hulka et al., 2014). We investigated the 
association between clinical measures and empathy and the association between plasma OXT values 
and empathy within MDMA users with correlation analyses (Pearson’s product-moment and 
Spearman’s rank correlation respectively) whereby we applied a significance threshold of p<.01 in 
order to avoid alpha error accumulation. To be able to assess the strength of group differences and 
their practical significance between controls and MDMA users, Cohen’s d effect sizes were calculated 
based on the means and pooled standard deviations (SD) of the two groups (Cohen, 1988).  
To analyze potential co-factors of cognitive empathy, we regressed the CES on the demographic 
variables age, sex, years of education, and verbal IQ (forced entry) over all participants and over 
MDMA users only. To analyze drug effects (within MDMA users) on cognitive empathy, we 
regressed CES on the MDMA hair analyses while retaining those demographic variables in the model 
that were significantly associated with CES. Because our MDMA user group showed, although 
minimal, co-consumption of other drugs, we additionally added amphetamine and cocaine hair 
analyses together with self-reported measures of cannabis, alcohol and nicotine consumption into the 
model according to previously published investigations of MDMA users (Wunderli et al., 2017). 
Because some of the drug use variables displayed a right-skewed distribution, we log-transformed 
(log10) these data after adding the constant 1 to those variables that included 0 values.  
Based on a post-hoc power analysis (after participant’s drug use was confirmed by hair analyses) with 
G*Power 3.1.9.2 (Faul et al., 2007), the main effects of the ANCOVAs in this study have an alpha-
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error probability of 5% and a power of 80% (assumed 6% variance explained by special effect, 24% 
variance explained by the covariates, and 70% error variance). The power analysis for our regression 
model investigating MDMA’s effect on cognitive empathy within MDMA users revealed a power of 
80% (one-tailed, assumed 13% variance explained by predictor, 12% by verbal IQ and 75% residual 
variance) (Shamay-Tsoory et al., 2004; Toussaint and Webb, 2005). 
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3.4 Results 
3.4.1 Demographic characteristics and drug use  
As intended by the application of our matching procedure, the groups did not differ significantly in sex 
distribution, age, verbal IQ, years of education, and depression scores (Table 1). For objective drug-
use measures, the median hair drug concentration for the MDMA users (n=38) was 2116 pg/mg and 
the middle 50% of hairs analyses fell between 881 pg/mg and 3530 pg/mg, whereas none of the 
controls had MDMA in their hairs.  
Moreover, 26 out of the 38 investigated MDMA users showed only minimal amphetamine and cocaine 
hair concentrations below the commonly accepted cut-off values (Society of Hair, 2004) of 200 pg/mg 
and 500 pg/mg respectively (Table S1). The remaining 12 MDMA users displayed amphetamine 
and/or cocaine hair concentrations above the mentioned cut-off values, but in each case also showed 
considerably higher MDMA hair concentrations. Therefore, we included all 38 (preferred) MDMA 
users to increase the power of our analyses (for detailed hair analyses of all MDMA users see Table 
S1). For self-reported cannabis parameters, MDMA users did not differ from controls for weekly 
cannabis use during the past half-year, duration of use, duration since last consumption, and in the 
amount of positive urine analyses. However, MDMA users reported a larger lifetime dose of cannabis. 
Finally, MDMA users did not differ from controls in any tobacco or alcohol use measures. 
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TABLE 1: Demographic data and drug use (means and standard deviations) 
 
 
Controls MDMA users value p df 
n 56 38 
   
Age, years 25.8 (6.1) 25.9 (6.2) -0.09 .93 92 
Years of school education 11.0 (1.6) 10.4 (1.9) 1.7 .10 92 
Verbal intelligence 103.9 (8.2) 102.7 (8.3) 0.70 .48 92 
BDI score 3.5 (3.8) 4.2 (4.4) -0.73 .47 92 
Sex (f/m) 26/30, 46.5 % f 18/20, 47.5% f 0.01 .93 1 
  
     
Tobacco 
     
Smoking status (y/n)a 41/15, 73.2% y 30/8, 78.9% y 0.40 .53 1 
Cigarettes per daya 7.3 (10.1) 7.2 (8.7) 0.01 .99 92 
Years of use 6.0 (6.6) 5.3 (5.5) 0.60 .55 92 
  
     
Alcohol 
     
Status (y/n)a 55/1, 98.2% y 38/0, 100.0% y 0.69 .41 1 
Grams per weeka 117.9 (132.0) 151.1 (121.9) -1.2 .22 92 
Years of use 8.7 (6.5) 6.3 (6.1) 1.8 .07 92 
  
     
Cannabis 
     
Status (y/n)a 30/26, 53.5% y 29/9, 76.3% y 5.0 .03 1 
Grams per weeka 0.44 (1.0) 0.60 (1.1) -0.67 .51 92 
Years of use 3.3 (3.7) 4.7 (5) -1.6 .11 92 
Cumulative dose (grams) 195.7 (504.6) 606.8 (1061) -2.5 .01 92 
Positive urine testing (n/y)b 48/7, 12,5% y 31/7, 18,4% y 0.57 .45 1 
Last consumption (days) 23.1 (32.9), n=30 17.5 (32.9), n=29 0.43 .51 57 
  
     
MDMA 
     
Status (y/n)a 0/56, 0.00% y 38/0, 100.0% y 94.0 <.001 1 
Tablets per weeka,c 0.00 (0.00) 0.90 (0.80) - - - 
Years of use 0.00 (0.00) 6.7 (6.1) - - - 
Cumulative dose (grams) 0.01 (0.04) 22.9 (27.7) -6.2 <.001 92 
Last consumption (days) - 25.1 (20.9), n=38 - - - 
Positive urine testing (y/n)b 0/56, 0.00% y 0/38, 0.00% y - - - 
Hair analysis pg/mg 0.00 (0.00) 4705 (8521) - - - 
  
     
Amphetamine 
     
Status (y/n)a 0/56, 0.00% y 22/16, 57.9% y 42.3 <.001 1 
Grams per weeka 0.00 (0.00) 0.03 (0.05) - - - 
Years of use 0.00 (0.00) 1.9 (2.9) - - - 
Last consumption (days) - 29.7 (33.8), n=22 - - - 
Cumulative dose (grams) 0.01 (0.03) 26.5 (107.3) 7.4 .07 92 
Positive urine testing (y/n)b 0/56, 0.00% y 0/38, 0.00% y - - - 
Hair analysis pg/mge 0.00 (0.00) 192.3 (689.5) - - - 
  
     
Cocaine 
     
Status (y/n)a 0/56, 0.00% y 20/18, 52,6% y 37.4 <.001 1 
Grams per weeka 0.00 (0.00) 0.11 (0.28) - - - 
Years of use 0.00 (0.00) 2.3 (3.6) - - - 
Last consumption (days) - 29.3 (35.3), n=20 - - - 
Cumulative dose (grams) 0.02 (0.05) 52.3 (150.6) 21.3 .01 92 
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Positive urine testing (y/n)b 0/55, 0.00% y 1/37, 0.03% y 1.5 .23 1 
Hair analysis pg/mg 0.00 (0.00) 578.8 (1344) - - - 
 
Significant p-values are shown in bold. Statistical tests: independent t-tests for quantitative data, χ2 tests for 
frequency data. 
BDI, Beck’s Depression Inventory 
Consumption per week, duration of use, and cumulative dose are averages within the total group. 
Last consumption is an average only for persons who reported to have used the drug within the past 6 months. 
In this case, sample size (n) is shown. One urine sample (control), the ADHD-SR data for one participant 
(MDMA user), the years of scool education for one particant (MDMA user), and the duration of MDMA use for 
one participant were missing. 
aDuring the past 6 months. 
bFor cut-offs, see the Supplementary Methods S1. 
cIn 100-mg tablets. 
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3.4.2 Social cognition 
For cognitive empathy, two-way ANCOVAs revealed a significant main effect of group on the 
cognitive empathy domain score (CES) (d=.62) (Figure 1). Both measures constituting the CES also 
differed between groups – the MASC sum score (d=.50) and the MET sum score (d=.39) – indicating 
a better cognitive empathy performance of MDMA users compared to drug-naïve controls (Table 2). 
These group differences were driven by a superior emotion identification of the MDMA users for 
emotionally positively charged pictures in the MET (d=.47) and a reduced tendency to overmentalize 
(overinterpreted perspective-taking) in the MASC (d=.51). Neither for the MASC sum score, the 
cognitive empathy performance in the MET, nor the CES a significant group*sex interaction was 
found (Table 2). 
Regarding emotional empathy (MET), no significant group and group*sex interaction effects occurred 
(p>.24). However, the factor sex showed a significant impact. As expected, women showed higher 
emotional empathy ratings (d=.58) for positively (d=.43) as well as negatively charged pictures 
(d=.63) (Table 2, Figure 2). 
 
TABLE 2: Emotional and cognitive empathy (means and standard errors) 
 
Significant p-values are shown in bold. Statistical test: Two-way ANCOVA with the factors group and sex and the covariate 
verbal IQ. CE, cognitive empathy, MASC, Movie for the assessement of social cognition, MET, Mulftifacetet empathy test,.  
aUsed for the cognitive empathy domain score. 
 
Controls MDMA users F df, dferr P_group p_IQ p_sex p_group_x_sex 
n 56 38  
   
  
MASC         
MASC sum correcta 34.8 (0.43) 36.4 (0.53) 6.0 1, 89 .02 .11 .81 .26 
MASC sum no TOM 1.9 (0.23) 1.3 (0.28) 2.5 1, 89 .12 .34 .60 .33 
MASC sum less TOM 3.3 (0.28) 3.4 (0.35) 0.03 1, 89 .87 .46 .30 .98 
MASC sum too much TOM 5.1 (0.30) 3.9 (0.36) 6.2 1, 89 .01 .36 .08 .36 
MET         
Emotional Empathy sum score (EES) 10.7 (0.31) 10.2 (0.37) 1.2 1, 88 .27 .93 .006 .35 
EES over positive pictures 10.3 (0.37) 9.6 (0.45) 1.6 1, 88 .21 .44 .04 .24 
EES over negative pictures 11.1 (0.31) 10.8 (0.37) 0.52 1, 88 .47 .46 .003 .65 
Cognitive empathy sum scorea 23.8 (0.48) 25.3 (0.57) 3.8 1, 88 .05 .001 .38 .52 
CE over positive pictures 12.5 (0.31) 13.6 (0.37) 5.6 1, 88 .02 .002 .23 .05 
CE over negative pictures 11.4 (0.36) 11.7 (0.43) 0.35 1, 88 .56 .09 .88 .39 
 
        
Cognitive empathy domain score 
(CES) 
-0.02 (0.10) 0.45 (0.12) 10.1 1, 88 .002 <.001 .48 .19 
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Figure 1: Differences in a combined cognitive empathy score between controls (n=56) and MDMA 
users (n=37). 
 
 
 
Estimated means and standard errors of the cognitive empathy domain score (CES). *p<.05. 
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Figure 2: Differences in emotional empathy between women (n=43) and men (n=50). 
 
 
 
Estimated means and and standard errors of emotional empathy ratings for all emotionally charged pictures, emotionally 
positively charged pictures, and emotionally negatively charged pictures. *p<.05, **p<.01. 
 
 
3.4.3 Social decision-making 
Averaged across the Distribution Game and the Dictator Game, MDMA users (mean combined Payoff 
A=63.2±13.5 SD) exhibited less self-serving behavior than controls (67.9±14.0) as indicated by a 
significant difference in the combined score Payoff A (F(1,90)=3.99, p<.05, d=.41). The effect was 
mainly driven by the Distribution Game, in which MDMA users acted less self-serving (d=.56) 
(Figure 3). Accordingly, in this game, 53% of the MDMA users chose the only fair point distribution 
(50:50 for player A and B) as opposed to 25% of the controls (χ2=7.50, p=.006, φ=.28).  
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Figure 3: Differences in self-serving behaviour between controls (n=56) and MDMA users (n=38). 
 
 
Estimated means and standard errors of the z-transformed payoff A (points participants gave to themselves) in 
the Distribution game and the Dictator game. **p<.01. 
 
3.4.4 Clinical measures 
MDMA users reported significantly more ADHD symptoms than controls (d=.66) (Table 3). In the 
BIS-11, the MDMA users displayed higher trait impulsivity (total score) compared with controls 
(d=.53). Likewise, significant main group effects were found for the subscales attentional 
impulsiveness (d=.41) and non-planning impulsiveness (d=.47). In the TCI, MDMA users differed 
from controls in novelty seeking (NS) scores (d=.57), driven by the sub-score disorderliness (NS4) 
(d=.52) (Table 3). Correlation analyses showed that severity of ADHD symptoms correlated 
significantly with BIS-11 attentional impulsiveness. Interestingly, TCI NS and NS4 scores neither 
correlated significantly with ADHD severity scores nor with BIS-11 scores (Supplementary Table S2). 
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TABLE 3: Clinical measures 
 
  Controls MDMA F df, dferr p 
n 56 38    
ADHD self-report rating scale (ADHD-SR)      
ADHD-SR sum score 7.7 (0.8) 12.0 (1.0) 10.7 1, 88 .001 
Barratt Impulsiveness Scale (BIS-11)      
BIS-11 Total score 62.0 (1.2) 66.8 (1.4) 6.5 1,89 .01 
  FI Attentional impulsiveness 14.3 (0.4) 15.6 (0.5) 4.0 1,89 .05 
  FII Motor impulsiveness 21.9 (0.5) 23.2 (0.6) 2.9 1,89 .09 
  FIII Nonplanning impulsiveness 25.9 (0.6) 28.0 (0.7) 4.8 1,89 .03 
Temperament and Character Inventory      
Self-directedness 33.8 (0.77) 32.4 (0.93) 1.4 1, 88 .24 
Cooperativeness 33.5 (0.69) 32.2 (0.83) 1.4 1, 88 .23 
Self-transcendence 10.8 (0.82) 12.1 (0.98) 0.92 1, 88 .34 
Harm avoidance 12.8 (0.76) 11.2 (0.91) 2.0 1, 88 .16 
Reward dependence 17.1 (0.48) 15.9 (0.58) 2.6 1, 88 .11 
Persistence 4.0 (0.28) 3.2 (0.33) 3.3 1, 88 .07 
Novelty seeking total score (NS) 22.3 (0.69) 25.4 (0.83) 7.8 1, 88 .007 
  NS1 Exploratory excitability 7.8 (0.27) 8.5 (0.32) 2.6 1, 88 .11 
  NS2 Impulsiveness 4.4 (0.32) 5.3 (0.38) 2.7 1, 88 .11 
  NS3 Extravagance 5.7 (0.27) 6.3 (0.32) 1.7 1, 88 .20 
  NS4 Disorderliness 4.3 (0.25) 5.3 (0.3) 6.3 1, 88 .01 
 
Estimated means and standard errors. Two-way ANCOVA (verbal IQ score as covariate, group and sex as factors). 
the ADHD-SR data for one participant (MDMA user) are missing. Significant p values are shown in bold.  
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3.4.5 Regression models 
To analyze potential co-factors on cognitive empathy, we regressed the CES on demographic variables 
(age, sex, years of education, and verbal IQ). This analysis over all participants (n=94) revealed 
significance for the verbal IQ coefficient (β=.344, t=3.31, p<.001) only (Supplementary Table S3). In 
a second step, we additionally introduced a grouping variable (MDMA users vs. controls) into the 
model. This grouping variable significantly predicted cognitive empathy (β=.301, t=3.11, p<.01). The 
amount of explained variance (corrected) increased significantly (p<.01) from 9% in the model 
without the grouping variable to 17% in the model with the grouping variable (R2corr=0.17, F5,87=4.70, 
p<.001).  
Within MDMA users (n=38), again, verbal IQ was the only demographic variable significantly 
associated with cognitive empathy (β=.408, t=2.33, p<.05). To analyze the effect of MDMA on 
cognitive empathy, we therefore regressed the CES on the MDMA hair analysis and the verbal IQ 
score. Interestingly, of the two predictors, only higher MDMA hair concentration significantly 
predicted lower cognitive empathy (β=-.324, t=-2.13, p<.05) (Figure 4 and Supplementary Table S4). 
Consequently, we excluded verbal IQ in a second step. The change in F was non-significant (p=.09). 
In a third step, we added amphetamine and cocaine hair concentration values, self-reported lifetime 
cannabis consumption (in grams), as well as the duration of alcohol and nicotine consumption into the 
model. Because no objective measures were available for cannabis, alcohol and nicotine consumption, 
self-reported variables were used to operationalize the influence of these substances. Importantly, the 
amount of explained variance did not increase (p=.60) by adding these drugs into the model and none 
of the coefficients predicted cognitive empathy except for MDMA (p<.05). In conclusion, group 
differences in cognitive empathy cannot be explained e.g., by the co-use of stimulants of the MDMA 
users. Finally, MDMA hair concentration did neither predict emotional empathy nor prosocial 
behavior in MDMA users (β=.194, t=.947, p=.35 and β=.251, t=1.008, p=.32, respectively). 
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Figure 4: Regression of cognitive empathy on MDMA hair concentrations (pg/mg). 
 
 
Regression of the CES z-score on the MDMA hair concentrations (log10) of the MDMA users (n=38), r(36) = -.34, p < .05, 
two-way. Higher hair values were associated with lower cognitive empathy. 
 
3.4.6 Oxytocin and empathy 
Blood plasma OXT levels were available for 9 controls and 24 MDMA users only. A Mann-Whitney 
test indicated no group difference in blood plasma OXT levels between controls (median=13.56 
pg/ml) and MDMA users (median=18.29 pg/ml), even though MDMA users unexpectedly showed 
moderately higher levels (U=139.0, p=.22, d=.42) (Figure 5). Within the MDMA users, blood plasma 
OXT levels did not correlate significantly with any MDMA use parameters. Moreover, women’s OXT 
levels were ranked higher than men’s were (rs=-.35, p<.05). Finally, in accordance with the gender 
effects on both emotional empathy and OXT plasma concentrations, we found that higher OXT levels 
were positively correlated with higher emotional empathy (rs=.44, p<.03) in MDMA users. 
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Figure 5: Mean peripheral blood plasma OXT levels (pg/ml) of controls (n=9) and MDMA users 
(n=24). 
 
 
 
Groups did not differ signifianctly (p>.05, d=.42). Circles represent female and dots represent male participants. 
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3.5 Discussion 
The aim of the study was to investigate empathy and social decision-making in objectively verified 
long-term MDMA users taking this drug as their main drug of choice. Detailed psychiatric diagnostics, 
hair toxicology, and matching were used to minimize the influence of psychiatric comorbidities and 
polydrug use. We showed that MDMA users display superior cognitive empathy compared with 
MDMA- and stimulant-naïve, healthy controls on one hand but that within MDMA users, increased 
MDMA hair contamination is associated with a decrease in cognitive empathy on the other hand. 
Additionally, MDMA users acted more pro-social than controls in the social decision-making tasks. 
Finally, the OXT system is likely not affected after long-term MDMA consumption, as peripheral 
OXY plasma levels were not significantly changed even though moderately elevated (d=0.42). In sum, 
these data suggest that recreational long-term MDMA users do not compensate for emotional empathy 
deficits by consuming MDMA (as no deficit was found), but rather show better cognitive empathy and 
pronounced prosocial behavior. 
In line with previous studies investigating MDMA and stimulant users in general (Morgan, 1998; 
Butler and Montgomery, 2004; Vonmoos et al., 2014), our sample of main MDMA users showed 
increased trait impulsivity (BIS-11) together with higher novelty seeking scores (TCI) compared with 
drug-naïve controls. This characterizes our sample of MDMA users as a typical recreational drug user 
sample as proposed before (Rounsaville, 2004; Vonmoos et al., 2013a; Maier et al., 2015). However, 
our sample of MDMA users might be special given that it encompasses 26 relatively pure and 
stimulant-free MDMA users (Table 1). Thus, our findings of a superior cognitive empathy and 
prosocial behavior in MDMA users might be valid only for relatively pure MDMA users and not for 
the more typical type of polydrug MDMA users (Schifano et al., 1998). Moreover, cognitive empathy 
and prosocial behavior were not correlated with ADHD symptoms, impulsivity and novelty seeking 
(Supplementary Table S2). Thus, our finding of superior cognitive empathy and prosocial behavior 
cannot be explained by elevated impulsivity and novelty seeking in MDMA users. Interestingly, the 
higher cognitive empathy of the MDMA users in this study were mainly driven by a superior 
identification of positive emotions in the MET compared to controls. Therefore one might conclude 
that either 1) MDMA chronically induces a “positivity bias” with regard to cognitive empathy or 2) 
that people with a predisposed emotional “positivity bias” prefer MDMA as a recreational drug. In line 
with our findings, Hysek et al. (2012) showed that MDMA acutely enhances the ability to interpret 
stimuli with positive emotional valence correctly. Moreover, also the emotional empathy for positive 
stimuli is increased acutely (Hysek et al., 2014b). Thus, the valence of emotional stimuli is of critical 
importance when considering acute and chronic effects of MDMA on measures of empathy. 
Using the same test battery, we have previously shown that relatively pure recreational and addicted 
cocaine users show impaired cognitive empathy (Hulka et al., 2013) and emotional empathy (Preller et 
al., 2014), which stands in strong contrast to the findings in MDMA users presented here. Hence, 
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although their personality traits (impulsivity and novelty seeking) resemble those of stimulant users, 
the group of relatively pure MDMA users seems to be a unique group of socially high performing drug 
users. This notion is further supported by our results regarding social decision-making as MDMA 
users, which, contrary to cocaine users (Hulka et al., 2014), acted more prosocial in the 
neuroeconomic games compared with controls. If this increased prosocial behavior of the MDMA 
users is a preexisting trait or rather a consequence of regular MDMA consumption cannot be 
explained by a cross-sectional study as the present one. Nevertheless, it seems plausible that repeated 
experiencing of interpersonal closeness leads to more prosocial behavior. Moreover, together with 
emotional empathy (empathic concern for others), cognitive empathy (mental and emotional 
perspective-taking) has previously been shown to correlate with affiliation motivation (Hill, 1987). 
More specifically, the underlying dimensions of positive stimulation – the tendency to receive 
gratification from harmonious relationships and from a sense of communion (Hill, 1987) – correlated 
highest with cognitive empathy. Thus, it seems likely that MDMA users display high affiliation 
motivation and that they use MDMA in social environments to satisfy this need for affiliation by 
MDMAs acute effect of enhanced emotional empathy (Hysek et al., 2014b).  
The results of the regression analysis for demographic variables emphasize our finding of superior 
cognitive empathy in MDMA users in two ways: First, the group contrast remains significant, even 
when the variables age und years of school education are held constant in addition to verbal IQ and 
sex. Second, almost half of the explained variance in cognitive empathy is explained by the group 
contrast. Notably, within MDMA users, our regression model was most efficient when only the hair 
toxicology analysis of MDMA was entered into the model, indicating a possible detrimental chronic 
effect of MDMA on social cognition as it was predicted from animal studies before (Boot et al., 2000; 
McGregor et al., 2008; van Nieuwenhuijzen et al., 2010). We are aware that causal interpretations of 
drug effects derived from a cross-sectional investigation are speculative. Nevertheless, the present 
results are in line with earlier studies from our group showing dose dependent impairment of executive 
functions in MDMA users (Quednow et al., 2006; Quednow et al., 2007). In fact, cognitive empathy 
has been shown to correlate with executive functioning before (Eslinger et al., 2011) and in our 
sample, a domain-score of executive functions – according to Vonmoos et al. (2013b) and Wunderli et 
al. (2016)  – was positively correlated with the MASC sum score (r(92)=.227, p<.05). Additionally, 
low recall consistency – as a measure for executive functioning – has been correlated with decreased 
glucose metabolism in the right dorsolateral prefrontal cortex in MDMA users in a recent PET study 
(Bosch et al., 2013). Given that adaptations in serotonin transporter density (McCann et al., 1998; Kish 
et al., 2010) as well as 5HT2A receptor density (Reneman et al., 2002) in the prefrontal cortex have 
been reported in MDMA users, changes in the prefrontal 5HT system might be responsible for the 
demonstrated decrease in cognitive empathy that went along with increased MDMA hair 
concentrations. Finally, it would be interesting to investigate cognitive empathy in a MDMA user 
sample in a longitudinal study in which premorbid cognitive empathy scores are gathered and empathy 
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scores together with sustained drug use are measured over time in order to answer the question if the 
here shown changes are predisposed or MDMA-induced. 
 
This study has some limitations. First, the common practice to measure drug use by means of self-
reported drug assessments has been criticized before (Cole, 2014). Therefore, we objectively 
quantified our participants drug use via hair toxicology analyses but still had to rely on self-reports for 
alcohol, nicotine, and cannabis consumption. Being aware of this problem, we aimed to minimize the 
influence of these drugs by matching the groups accordingly. Second, we cannot rule out that the 
superior cognitive empathy of MDMA users is in fact a consequence at least of light or moderate 
MDMA consumption. Likewise, the implicated detrimental effect of MDMA on cognitive empathy is 
based only on the correlation between past drug use (hair analyses) across the last 3-6 months and 
current cognitive empathy. We therefore suggest that future research investigates this relationship in a 
longitudinal study. Third, our sample comprises 26 stimulant-free, pure MDMA users and might 
therefore not be generalizable to the prototypical recreational polydrug MDMA user. Fourth, our 
exploratory investigation of blood plasma OXT is based on a rather small sample size (n=24 users vs. 
n=9 controls). Moreover, peripheral OXT levels might not reflect the status of the neural OXY system 
(Kagerbauer et al., 2013). Therefore, the possibility of a long-term MDMA consumption effect on 
neural OXT systems still cannot be ruled out. We suggest that blood plasma OXT values of long-term 
MDMA users are compared to MDMA-naïve controls in a bigger sample in which sex is distributed 
evenly between groups. Moreover, an OXY receptor radioligand should be developed to investigate 
the status of the cerebral OXY system in human MDMA users by positron emission tomography. 
 
Taken together, our data suggest that primary MDMA users show personality traits comparable to 
recreational stimulant users, but in contrast to those show superior cognitive empathy and more pro-
social behavior than drug-naïve, healthy controls. Primary MDMA users might therefore be described 
as socially high performing drug users. However, because severe chronic MDMA consumption seems 
to have a toxic effect on cognitive empathy, we suggest that the superior cognitive empathy of MDMA 
users is not a consequence of MDMA use, but rather a predisposition for it. We conclude that main 
MDMA users do not consume MDMA to compensate for emotional empathy deficits, but are more 
prone to MDMA consumption because of pronounced cognitive empathy likely going along with high 
affiliation motivation. 
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3.7 Supplementary material 
3.7.1 Methods 
Methods S1: Urine and hair toxicology  
Urine toxicology analyses comprised the following substances: tetrahydrocannabinol, cocaine, 
amphetamines, benzodiazepines, opioids, and methadone and were assessed by a semi-quantitative 
enzyme multiplied immunoassay method using a Dimension RXL Max (Siemens, Erlangen, 
Germany). For the detection of illegal drug use, the following cut-offs have been applied (Bush, 
2008): Cannabis, 50 ng/ml; cocaine, 150 ng/ml; and amphetamines, 500 ng/ml.  
To objectively characterize drug use over the last six months, hair samples were collected and 
analyzed with liquid chromatography-tandem mass spectrometry (LC-MS/MS). The proximal hair 
segment of a length of up to 6 cm was examined. The following 17 compounds were assessed: 
cocaine, benzoylecgonine, cocaethylene, norcocaine, amphetamine, methamphetamine, MDMA, 
MDEA, MDA, morphine, codeine, methadone, EDDP (primary methadone metabolite, 2-ethylidene-
1,5-dimethyl-3,3-diphenylpyrrolidene), tramadol, 2C-B, ketamine, and methylphenidate.  
For our routine protocol for drugs of abuse analysis a three-step washing procedure with water (2 
minutes shaking, 15ml), acetone (2min., 10ml) and finally hexane (2min., 10ml) of hair was 
performed. Then the hair samples were dried at ambient temperatures, cut into small snippets and 
extracted in two steps, first with methanol (5ml, 16 hours, ultrasonication) and a second step with 3 ml 
MeOH acidified with 50 µL hydrochloric acid 33 % (3 hours, ultrasonication). The extracts were dried 
and the residue reconstituted with 50 µL MeOH and 500 µL 0.2 mM ammonium formate (analytical 
grade) in water. As internal standards deuterated standards of the following compounds were used, 
added as mixture of the following compounds: cocaine-d3, benzoylecgonine-d3, ethylcocaine-d3, 
morphine-d3, MAM-d3, codeine-d3, dihydrocodeine-d3, amphetamine-d6, methamphetamine-d9, 
MDMA-d5. MDEA-d6, MDA-d5, methadone-d9, EDDP-d3, methylphenidate-d9, tramadol-d3, 
oxycodone-d3, and ephedrine-d3. All deuterated standards were from ReseaChem (Burgdorf, 
Switzerland), the solvents for washing and extraction were of analysis grade and obtained from Merck 
(Darmstadt, Germany); LC-solvents were of HPLC grade and were obtained from Sigma Aldrich 
(Buchs, Switzerland). 
The LC-MS/MS apparatus was an ABSciex QTrap 3200 (Analyst software Version 1.5, Turbo V ion 
source operated in the ESI mode, gas 1, nitrogen (50 psi); gas 2, nitrogen (60 psi); ion spray voltage, 
3500V; ion source temperature, 450°C; curtain gas, nitrogen (20 psi) collision gas, medium), with a 
Shimadzu Prominence LC-system (Shimadzu CBM 20 A controller, two Shimadzu LC 20 AD pumps 
including a degasser, a Shimadzu SIL 20 AC autosampler and a Shimadzu CTO 20 AC column oven, 
Shimadzu, Duisburg, Germany). Gradient elution was performed on a separation column (Synergi 4µ 
POLAR-RP 80A, 150x2.0 with a POLAR-RP 4x2.0 Security Guard Cartridge, (Phenomenex, 
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Aschaffenburg, Germany). The mobile phase consisted of 1mM ammonium formate buffer adjusted to 
pH 3,5 with formic acid (eluent A) and acetonitrile containing 1mM ammonium formate and 1 mM 
formic acid (eluent B). The analysis was performed in MRM mode with two transitions per analyte 
and one transition for each deuterated internal standard, respectively. According to the Society of Hair 
Testing (Society of Hair, 2004), the following cut-offs have been applied: cocaine, 500 pg/mg; 
amphetamine, 200 pg/mg; and MDMA, 200 pg/mg. 
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3.7.2 Results 
Table S1. Hair analyses results (concentration values in pg/mg) of self-reported MDMA users and 
MDMA group allocation. 
 
 
For each participant, the amount of metabolites per substance (pg/mg) are shown. The cocaine metabolites benzoylecgonine, 
cocaethylene, and norcocaine are not shown. Tramadol is not shown because it was not detected in any subject. Strong stimulant co-
consumption use leading to exclusion is shown in bold. To be included into the MDMA user group, hair samples had to reveal a 
larger MDMA concentration compared to cocaine and amphetamine values. To be classified as a pure MDMA user, hair samples had 
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to reveal a cocaine value <500pg/mg and an amphetamine value <200pg/mg (Cooper et al., 2012). Illicit drugs were not detected in 
the participants of the control group. 
1Analyzed hair length from scalp in cm.  
2C-B, 2,5-dimethoxy-4-bromphenethylamine; EDDP, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidene; ex, excluded; MDMA, 
3,4-methylendioxy-N-methylamphetmanine; MDEA, 3,4-methylendioxy-N-ethylamphetmanine; MDA, 3,4-
methylendioxyamphetamine; n.a., not available. 
 
Study 2 – MDMA and social cognition 85 
Table S2. Correlation analyses between clinical measures and social cognition in MDMA users 
(n=38). 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
1) BIS-11 total score  1 .605*** .734*** .494** .276 -.243 -.187 .117 -.075 .174 .314 .214 
2) BIS-11 attentional impulsiveness  1 .118 .123 .114 -.059 -.031 .016 -.015 .149 .474** .280 
3) BIS-11 non-planning impulsiveness   1 .351 .071 -.200 -.298 .134 -.152 -.028 -.115 -.127 
4) TCI novelty seeking    1 .694*** -.071 -.072 -.085 -.110 .191 .104 .094 
5) TCI disorderliness     1 -.046 -.036 -.046 -.057 .332 .189 .140 
6) MET emotional empathy      1 .136 -.448** -.172 -.050 -.041 .057 
7) MASC sum score       1 -.011 .783*** .043 -.027 .158 
8) MET cognitive empathy sum score        1 .613*** .065 -.171 -.087 
9) Cognitive empathy domain score         1 .075 -.132 .071 
10) Self-serving behavior (Payoff A)          1 .154 .224 
11) ADHS-SR sum score           1 .410 
12) BDI sum score            1 
 
Correlation coefficients are shown and p-values are indicated as follows: **p<.01, ***p<.001. 
An ADHD-SR questionnaire of one participant was missing. 
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Table S3. Multiple Regression analysis for demographic variables predicting cognitive empathy 
(controls and MDMA users). 
 
  B SE B β T-value p R
2
corrected p change in F 
Step 1      .086 .018 
Constant -2.388 1.087   -2.198 .03   
Sex -.137 .158 -.089 -.866 .39   
Age -.023 .014 -.178 -1.652 .10   
Years of school education -.014 .046 -.031 -.296 .77   
Verbal IQ .033 .010 .344 3.310 .001   
Step 2      .168 .003 
Constant -9.623 2.547   -3.778 <.001   
Sex -.121 .151 -.078 -.800 .43   
Age -.021 .013 -.169 -1.639 .11   
Years of school education .008 .045 .019 .185 .85   
Verbal IQ .034 .009 .362 3.647 <.001   
MDMA users vs. controls .470 .151 .301 3.110 .003   
 
Dependent variable: Cognitive empathy score (z-score). Significant p-values are shown in bold. 
Step 1: R2 = .13 and F = 3.152, p=.018. 
Step 2: R2 = .21 and F = 4.725, p<.001. 
N = 94 (56 controls and 38 MDMA users).  
The data met the assumption of independent errors (Durbin-Watson value = 2.16). 
B = regression coefficient, SE B = standard error, β = standardized Beta. 
Females were coded with 0 and males with 1 for the sex variable.  
For the group comparison, controls were coded with 0 and MDMA users with 1. 
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Table S4: Multiple Regression analysis for drug use variables predicting cognitive empathy (only 
MDMA users). 
 
 
B SE B β 
T-
value 
p R2corrected 
p change in 
F 
Step 1      .143 .025 
Constant -.861 1.556  -.553 .584   
Verbal IQ .024 .014 .271 1.775 .085   
MDMA hair concentration (pg/mg) -.374 .176 -.324 -2.128 .040   
Step 2      .092 .085 
Constant 1.701 .600   2.836 .007   
MDMA hair concentration (pg/mg) -.393 .181 -.341 -2.177 .036   
Step 3      .058 .600 
Constant 1.965 .717   2.742 .010   
MDMA hair concentration (pg/mg) -.575 .222 -.499 -2.589 .015   
Amphetamine hair concentration 
(pg/mg) 
.190 .113 .292 1.683 .102   
Cocaine hair concentration (pg/mg) .036 .103 .066 .347 .731   
Cannabis lifetime dose (g) -.029 .106 -.046 -.273 .786   
Alcohol (years of use) .066 .346 .033 .191 .850   
Nicotine (years of use) .134 .302 .078 .445 .659   
 
Dependent variable: Cognitive empathy score (z-score). Significant p-values are shown in bold. 
Step 2: R2 = .12 and F = 4.739, p=.036. 
N = 38 primary MDMA users.  
The data met the assumption of independent errors (Durbin-Watson value = 2.34). 
B = regression coefficient, SE B = standard error, β = standardized Beta, g/week = grams per week, pg/mg = 
picogram per milligram. 
All predictors (except for verbal IQ) were log-transformed (base 10). 
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This doctoral thesis investigated chronic effects of MDMA use on social and non-social cognitive 
performance by comparing relatively pure users of MDMA with MDMA- and stimulant-naïve 
controls. In the first study, we investigated the detrimental effects of stimulant co-use by including a 
third group of MDMA polydrug users mainly co-using MDMA with stimulants such as amphetamines 
and cocaine. A special feature of both investigations is the objective measurement and description of 
the participants drug use by quantitative hair analyses. Because of these measures, we were able to 
distinguish between probably stimulant induced impairments regarding cognitive performance in the 
first study and to statistically rule out polydrug use as an explaining factor in the second study.  
In what fallows, the main findings of the two papers together with their strengths and limitations will 
be briefly summarized. The first study investigated attention, working memory, declarative memory 
and executive functions in relatively pure MDMA users in contrast to MDMA- and stimulant-naïve 
controls as well as polydrug MDMA users. The second study investigated social cognition and 
decision making in main MDMA users in contrast to MDMA- and drug-naïve controls.  
 
4.1 Cognitive performance of pure vs. polydrug MDMA users 
The results of the first study are in line with previous meta-analyses (Kalechstein et al., 2007; Laws 
and Kokkalis, 2007; Rogers et al., 2009) and confirmed our hypothesis that the strongest impairments 
in pure as well as polydrug MDMA users are found in declarative memory performance. Additionally, 
they show that even in almost pure MDMA users considerably large declarative memory deficits 
occur. In all four cognitive domains, effect sizes of cognitive impairment of pure MDMA users were 
between controls’ and polydrug MDMA users’, whereby – besides declarative memory – also working 
memory performance differed significantly from controls. This is in line with Rogers et al. (2009), as 
verbal declarative memory and working memory were the two most impaired cognitive functions in 
MDMA users in their meta-analysis too. By the means of regression analyses, we investigated 
potential co-factors and dose-response effects on declarative memory performance. This analysis over 
all participants strengthened our finding as group contrasts remained significant even when sex, age, 
and verbal IQ were held constant. These three variables are of special interest in the context of long-
term deficits in MDMA users. 1) Women were shown to be more susceptible to MDMA-induced 
neurotoxic effects (SERT reduction) (Reneman et al., 2001) than males. 2) Age is associated with a 
decline in cognitive processes, specifically in attention and memory tasks (Allott and Redman, 2007) 
while 3) verbal IQ is a correlate of global cognitive abilities. Similarly, also ADHD and depression 
scores did not significantly contribute to the regression model, while group contrasts remained 
significant. This was surprising as we have shown an association between ADHD as well as 
depression scores and cognitive difficulties in cocaine users before (Vonmoos et al., 2013b; Wunderli 
et al., 2016) and was probably due to our exact matching procedure which lead a reduced variance in 
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depression and ADHD scores. Additionally, it is also possible that – in contrast to cocaine – MDMA 
does not interact with depression or ADHD scores. 
Interestingly, neither MDMA hair concentrations nor the MDMA lifetime dose predicted memory 
performance significantly. Although some studies have found correlations between lifetime MDMA 
consumption and cognitive deficits (Gouzoulis-Mayfrank et al., 2000; Quednow et al., 2006), this non-
finding is in line with the theory of a stepwise relationship between MDMA use and memory decline 
(Laws and Kokkalis, 2007). According to this idea, a one-off recreational dose may be responsible for 
a negative effect and later recreational consumption does no further harm (Verbaten, 2003; Laws and 
Kokkalis, 2007). Finally, we showed that within MDMA users, the lifetime consumption of cannabis 
was significantly associated with a decline in declarative memory (besides the group contrast). This is 
in line with a large body of literature connecting cannabis use with cognitive impairments (Curran et 
al., 2016) and shows, that in drug research, cannabis consumption must be considered when 
interpreting results.  
In sum, these results indicate a strong risk for broad cognitive impairments in polydrug MDMA users 
and show that even relatively pure MDM A users show robust impairments in declarative memory. 
Finally, the strong working memory and executive function impairments in polydrug MDMA users 
seem to be driven by their stimulant co-use.   
4.2 Social cognition and decision making of main MDMA users 
The second study confirmed previous findings investigating MDMA and stimulant users (Morgan, 
1998; Butler and Montgomery, 2004; Ersche et al., 2011; Vonmoos et al., 2014) in as far as our 
MDMA users displayed elevated measures of impulsivity and novelty seeking compared with 
controls. Therefore, our sample of main MDMA users shows trait measures that are considered typical 
for recreational drug user samples (Rounsaville, 2004; Vonmoos et al., 2013a; Maier et al., 2015). 
This is of interest because our finding of a superior cognitive empathy of main MDMA users 
compared with controls might else be rejected with the argument of an over performing sample which 
is well educated, intellectual, and cognitively high performing. To examine cognitive empathy, we 
correlated cognitive empathy performance with a variety of clinical measures including ADHD and 
depression scores. None of these correlations were significant. This further supports our finding of an 
increased cognitive empathy in main MDMA users as group differences are not attributable to 
differences in clinical measures. This therefore additionally strengthens the association between our 
MDMA user sample and it’s increased cognitive empathy on the one hand. On the other hand, also our 
finding of a decline in cognitive empathy that goes along with increased MDMA hair values is 
supported, as this decrease cannot be attributed to ADHD and depression scores within MDMA users.  
In addition to an increased cognitive empathy, our sample of main MDMA users also displayed less 
self-serving behavior in our task of social decision making. This finding was in contrast to Hulka et al. 
(2014) who reported decreased prosocial behavior in a cocaine user sample. However, the increased 
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prosocial behavior of our main MDMA users in comparison to the control group together with their 
cognitive empathy abilities suggests, that MDMA user with little to none stimulant co-use can be 
described as socially high performing drug users. Interestingly though, the MDMA users did not differ 
from controls in emotional empathy measures, which is what we would have expected given the 
functual linkage between emotional empathy and OXT (Thompson et al., 2007; Kirkpatrick et al., 
2014).  
Our findings regarding OXT levels in MDMA users in comparison to controls did not support findings 
of OXT depletion after repeated MDMA administration coming from animal studies (van 
Nieuwenhuijzen et al., 2010). Indeed, our MDMA sample even showed slightly higher OXT blood 
plasma levels. However, this difference did not reach significance probably due to the low power of 
this comparison. However, according to existing literature that reported higher emotional empathy and 
higher OXT levels in women (Fukushima and Hiraki, 2006; Rueckert and Naybar, 2008), we found 
that higher OXT levels did positively correlate with higher emotional empathy. This strengthens the 
validity of our OXT measures and therefore these findings could motivate future research to 
investigate the possible elevation of OXT levels in MDMA users.  
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4.3 Strengths 
The design of the studies constituting this thesis has a number of strengths worth mentioning.  
First, the use of urine and hair analyses enabled us to monitor recent polydrug as well as past drug use 
over the past six month respectively. Urine toxicology analyses are considered to be accurate in 
detecting recent cocaine and amphetamine consumption (Moeller et al., 2008), the most co-used drugs 
in our sample. As urine toxicology analyses in our studies were performed by semi-quantitative 
enzyme multiplied immunoassays, it must be noted that results are presumptive only, although using 
urine analyses is considered common practice in drug research nowadays (Moeller et al., 2008). Thus, 
we did not exclude urine positive participants because of power considerations, according to other 
publications from the ZuCo2St (Vonmoos et al., 2013b; Hulka et al., 2014; Preller et al., 2014). 
Unfortunately, our urine analyses did not screen for MDMA, as amphetamine immunoassays show a 
low sensitivity for the detection of MDMA (Hsu et al., 2003; Moeller et al., 2008). We therefore relied 
on the hair toxicology analyses. This enabled us to quantify objectively the participants’ drug use for 
up to six month. Accordingly, we excluded two participants from the analyses because of a lack of 
hair and additional 13 participants in study 2, as their stimulant co-consumption exceeded their 
MDMA use.  
Second, trained psychologists conducted the SCID I in order to exclude participants with a severe 
Axis-I disorder. In addition, participants were also excluded if close relatives were diagnosed with 
these disorders because of possible genetic components (schizophrenia, obsessive-cumpulsive 
disorder, eating disorder, etc.).  
Third, subclinical levels of ADHD and depression were considered in both studies in the regression 
models in order to evaluate their impact on declarative memory and cognitive empathy, as both 
ADHD and depression are associated with drug abuse in general (Swendsen and Merikangas, 2000; 
Regnart et al., 2017). 
Fourth, we assessed the personality structure of our sample by applying the BIS-11 and the TCI 
(reported in study 2). We therefore were able to characterize our sample even more precisely and show 
that our sample of MDMA users resembles typical recreational drug users. 
Fifth, although our samples were not huge, they can be considered large in comparison to other cross-
sectional studies investigating MDMA user. Consequently, main effects in both studies had an alpha-
error probability of 5% and a power of 85% and 80% respectively.  
Fifth, evidence for MDMA induced cognitive impairments accumulated in the past 30 to 40 years 
(Kelly, 2000; Parrott, 2014). The results of our first study are in line with these findings and extend the 
existing literature by eliminating the often-applied criticism of self-reported drug use. Regarding 
social-cognition, our second study showed increased cognitive empathy and prosocial behavior in 
main MDMA users, but also a decline in cognitive empathy with increased MDMA hair values. We 
therefore propose that an increased cognitive empathy and prosocial behavior are predisposing traits of 
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people especially prone for long-term MDMA consumption and deliver evidence for a possible 
detrimental effect of MDMA use on social cognition for the first time.  
 
 
4.4 Limitations  
Besides the outlined strengths of our studies mentioned before, there are some limitations to consider. 
Although urine toxicology analyses were used to verify the absence of recent drug use such as 
amphetamine, cocaine, benzodiazepines, cannabis, methadone, and opioids, we had to rely on 
participants’ self-reported abstinence duration for MDMA use. Additionally, we had to rely on self-
reports for the consumption parameters of alcohol, nicotine, and cannabis, but we minimized the 
influences of these variables by matching. A further limitation that should be mentioned is that also 
pure and main MDMA users consumed alcohol, nicotine, and cannabis. We tried to control the effects 
of these substances by matching the groups accordingly, but we remain unaware of possible 
interaction effects between MDMA and these substances.  
Besides the limitations already mentioned in study one and two, some test specific weaknesses of the 
applied tasks in the two studies that deserve mentioning. In the first study, we operationalized 
declarative memory by combining variables from the RAVLT and the PAL according to previous 
publications from the ZuCo2St (Vonmoos et al., 2013b; Wunderli et al., 2016). Although verbal 
(RAVLT variables) as well as visual (PAL) aspects of declarative memory are measured with these 
variables, they measure the retrieval of memories that have been stored for a maximum of around 30 
minutes only. In the second study, the domain of cognitive empathy consisted of the MASC sum score 
and the cognitive empathy sum score from the MET. For the MASC, Dziobek et al. (2006) noted that 
all of the actors in the movie have roughly the same (mid-thirties). Because our participants had an 
average age of around 26 years and the age of the actors serves as the context in which social 
cognition has to be assessed in MASC, one might argue that scenes with actors with a wider age range 
would be more optimal. Another downside of the MASC might be that the movie is rather 
uninteresting to watch and that the task takes around 30 minutes to complete. Attentional as well as 
motivational differences between participants might therefore influence their performance.  
Finally, a cross-sectional study does not allow causal conclusions about the direction of the relation 
between to associated variables. In the context of our studies, this means that MDMA cannot be 
labeled the cause of declarative memory deficits and a decline of cognitive empathy. Nevertheless, our 
results strongly imply this relationship in the context of the large body of literature including 
longitudinal investigations in humans (e.g. Wagner et al., 2015), already pointing in this direction. 
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4.5 Implications and Perspectives 
The main aim of this behavioral research in MDMA users is to extend the knowledge on the relation 
between MDMA use and social and non-social cognitive processes. Particularly because an increase in 
worldwide MDMA consumption has been observed in recent years (United Nations Office on Drugs 
and Crime, 2016, 2017) there is the need to better understand consequences of long-term MDMA use 
in order to better estimate possible detrimental chronic effects of this substance. Although cognitive 
consequences of MDMA use were already well-documented in MDMA users (Fox et al., 2001; 
Montgomery et al., 2005; Quednow et al., 2006; Quednow et al., 2007) and a number of reviews have 
been published on the topic (Parrott, 2001; Laws and Kokkalis, 2007; Rogers et al., 2009; Parrott, 
2013), our research extended the knowledge about consequences of MDMA use by eliminating the 
confounding effects of stimulant co-use and by investigating social cognition and decision making in 
an objectively verified main MDMA user sample for the first time. Although the presented studies do 
not conclude concrete instructions about how to translate the finding into a clinical setting, they clearly 
imply how future behavioral MDMA research (and drug research in general) could and should be 
improved. 
First, results from the first study show that concurrent or even contemporary consumption of MDMA 
and stimulants should be avoided, because of stronger cognitive impairments in polydrug MDMA 
users in comparison to relatively pure MDMA users. This is line with animal studies showing that the 
combined administration of MDMA and prodopaminergic agents leads to a potentiation of 
serotonergic neurotoxic effects of MDMA (Johnson et al., 1991; Johnson and Nichols, 1991; Schmidt 
et al., 1991; Clemens et al., 2005) and is of concern in the context of the repeatedly shown variability 
in the purity of MDMA tablets (Morgan, 1999; Parrott, 2004). For future research, our finding of 
stronger cognitive impairments in polydrug MDMA users therefore implies the need for objective 
drug use and group assessments. In addition to stimulant co-use, the need for a reliable assessment of 
cannabis consumption is implicated by the results of our first study too. This need is underlined by the 
fact that MDMA users often co-use cannabis on a regular basis (Parrott et al., 2007). However, it was 
not possible to determine THC-metabolites in hair in our study. 
Second, our second study on social cognitive functioning indicates that main MDMA users with little 
to none stimulant co-use can be considered socially high-performing, while they yet display trait 
impulsivity and novelty seeking measures comparable to recreational stimulant users. Because an 
increased impulsivity is linked to a higher risk of stimulant abuse (Verdejo-Garcia et al., 2008; de Wit, 
2009; Ersche et al., 2010; Vonmoos et al., 2013a), our data suggest that long-term pure MDMA 
consumers could be a reasonable target of drug abuse prevention programs with the aim to prevent 
them from engaging in regular stimulant use.  
Third, the ZuCo2St revealed that social and non-social cognition are strongly moderated by comorbid 
ADHD symptoms in cocaine users (Vonmoos et al., 2013b; Preller et al., 2014) and we recently 
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reported detrimental interaction effects between cocaine use and ADHD on cognitive empathy/ToM 
(as measured by the MASC) (Wunderli et al., 2016). We did not find this moderating effect of ADHD 
on cognition nor social cognition in the two studies presented in this thesis. This may be due to the 
overlap of the brain systems altered in ADHD with the dopaminergic, cocaine-impacted 
neurotransmitter systems that differs from the serotonergic system impacted by MDMA and also play 
a crucial role in the etiology of ADHD (Tripp and Wickens, 2009). 
Fourth, regarding the differences in peripheral OXT levels in MDMA users discussed before, we 
propose that future research investigates the impact of chronic MDMA consumption on neural OXT 
levels. By developing a radioligand to measure OXT receptor density in humans by positron emission 
tomography, future research could answer the question if chronic MDMA use alters the neural OXT 
system but also, if peripheral OXT levels really mirror the neural ones, which was critically discussed 
before (Kagerbauer et al., 2013) .  
Fifth, our main MDMA user sample in study 2 included 26 non-stimulant using MDMA users. 
Because therefore our results may not be generalizable to typical (polydrug using) MDMA users 
(Schifano et al., 1998), social cognition and decision making should be investigated in a more typical 
MDMA user sample in the future.  
Sixth, the amount of self-reported MDMA use fluctuates between studies because 1) participants 
might be motivated to give a biased self-report and 2) because participants might over- or 
underestimate their own drug use. Additionally, regional differences in drug availability and drug use 
culture may also induce differences in drug use samples across studies. For example, Quednow et al. 
(2006) investigated MDMA users with a mean cumulative lifetime dose of 460 tables, Montgomery et 
al. (2005) investigated a sample reporting a mean lifetime consumption of 346 tablets, and the main 
MDMA users of our second study reported a mean MDMA lifetime dose of 229 tablets. As we were 
able to find significant regression coefficients for MDMA hair values, which only capture the past half 
year, already, one has to be aware of these differences when interpreting results.  
Seventh, finally, it would be interesting to investigate cognition and non-social cognition in an 
objectively verified MDMA user sample in a longitudinal setting. By measuring premorbid cognitive 
and social cognitive performance and by repeated collection of hair samples, a continuous tracking of 
the drug intake of every participant would be possible. For the issue that human participants cannot be 
asked to engage in chronic MDMA use for the sake of a longitudinal investigation, a compelling 
solution was found by Wagner et al. (2015). The authors included inexperienced MDMA users (less 
than 6 tablets) with a high probability of future MDMA consumption into their longitudinal analysis. 
Such a design (together with a non-MDMA and non-drug using control group) would allow for causal 
conclusions about the relationship between chronic MDMA use and social and non-social cognitive 
impairments.  
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